Cell senescence and aging in carcinogenesis and liver repopulation by unknown
  
 
 
Università degli Studi di Cagliari 
 
DOTTORATO DI RICERCA 
SVILUPPO E SPERIMENTAZIONE DEI FARMACI ANTIVIRALI 
Ciclo XXIV 
 
 
CELL SENESCENCE AND AGING 
IN CARCINOGENESIS AND LIVER REPOPULATION 
 
Settore/i scientifico disciplinari di afferenza 
BIO/19    MED/04 
 
 
Presentata da:                         MARIA PAOLA SERRA 
Coordinatore Dottorato    ALESSANDRA PANI 
Tutor/Relatore              EZIO LACONI 
 
 
Esame finale anno accademico 2010 - 2011 
 
  
 
Table of Contents 
 
 
1 Summary ..................................................................................................................................... 1 
2 Introduction ................................................................................................................................ 6 
2.1 Foreword .............................................................................................................................. 6 
2.2 Cell Senescence .................................................................................................................... 7 
2.2.1 Characteristics of senescent cells ................................................................................. 9 
2.2.2 The DNA damage response and cell senescence........................................................ 10 
2.2.3 Factors inducing cellular senescence.......................................................................... 12 
2.2.4 The secretory phenotype of senescent cells .............................................................. 19 
2.2.5 Biomarkers of cellular senescence ............................................................................. 23 
2.2.6 Cellular Senescence and Inflammation ...................................................................... 27 
2.2.7 Cellular senescence and aging. ................................................................................... 30 
2.3 Aging ................................................................................................................................... 31 
2.2.1. Aging and cancer......................................................................................................... 33 
2.4 Regenerative medicine: the liver as a model. .................................................................... 34 
2.4.1 Association between Liver Repopulation and Carcinogenesis. .................................. 37 
3 Aim ............................................................................................................................................. 39 
4 Materials and Methods .......................................................................................................... 40 
4.1 Animals and treatments ..................................................................................................... 40 
4.2 Retrorsine ........................................................................................................................... 40 
4.3 Generation of hepatic nodules ........................................................................................... 42 
4.4 The dipeptidyl-peptidase type IV-deficient rat model for hepatocyte transplantation ..... 42 
4.5 Staining for senescence associated β-galactosidase activity .............................................. 43 
4.6 Histology, Immunohistochemistry and Immunoflorescence ............................................. 43 
4.7 Western Blot ....................................................................................................................... 44 
4.8 RNA Isolation, RT-PCR and Real-Time qPCR ....................................................................... 45 
4.9 DNA liver content ............................................................................................................... 45 
 
  
5 Results ....................................................................................................................................... 48 
5.1 The microenvironment of the aged rat liver supports the growth of transplanted 
hepatocytes isolated from hepatic nodule..................................................................................... 49 
5.1.1 Beta-galactodidase ..................................................................................................... 53 
5.1.2 Expression of IL-6 in animals of different age............................................................. 54 
5.1.3 Inhibitors of cell cycle regulation ................................................................................ 55 
5.2 Cell senescence in liver repopulation ................................................................................. 56 
5.2.1 RS-exposed hepatocytes express senescence-associated β-galactosidase. ............... 56 
5.2.2 Hepatocyte megalocytosis induced by RS. ................................................................. 57 
5.2.3 DNA damage foci in RS-treated rat liver. .................................................................... 59 
5.2.4 Up-regulation of cell cycle inhibitory proteins in RS-treated  rat liver. ...................... 61 
5.2.5 The increased expression of positive regulators of cell growth and cell-cycle 
progression in RS-exposed liver. ................................................................................................. 64 
5.2.6 IL-6 is over-expressed in rat liver exposed to RS. ....................................................... 65 
5.2.7 Regulation of IL-8 following exposure to RS ............................................................... 67 
5.2.8 Up regulation of TNF-α ............................................................................................... 67 
5.2.9 Regenerative nodules do not express markers of cell senescence. ........................... 68 
5.3 Normal hepatocyte transplantation delays the emergence of chemically-induced pre-
neoplastic nodules in rat liver ........................................................................................................ 71 
5.3.1 The induction of hepatic nodules by sequential exposure to DENA+RS. ................... 72 
5.3.2 Liver size and hepatocyte proliferation. ..................................................................... 74 
5.3.3 Liver repopulation by transplanted cells in DENA+RS-treated liver. .......................... 75 
5.3.4 The effect of hepatocyte transplantation on the incidence of nodules in the liver of 
DENA+RS-treated rats. ................................................................................................................ 76 
5.3.5 SA-β-GAL decrease in transplanted animals ............................................................... 78 
5.3.6 DNA damage foci ........................................................................................................ 79 
6 Discussion ................................................................................................................................. 81 
7 References ................................................................................................................................ 90 
 
 
 
 
 1   
 
1 Summary 
 
 Aging is the strongest risk factor for neoplastic disease. The hypotheses that have 
been proposed to explain this association can be grouped into two broad 
categories. 
 One is a “cell-orientated” hypothesis, and focuses on alterations (mainly genetic) 
taking place in rare cells in a tissue such that they eventually acquire a full 
malignant phenotype. Within this framework, aging can increase the risk of cancer 
by various mechanisms, such as (i) simply allowing more time for random mutations 
to occur in a single cell, or (ii) by increasing the generation of DNA damaging 
metabolites (e.g. through chronic inflammation), or  (iii) by decreasing the efficiency 
of DNA repair processes and/or antioxidant defences. 
 A second, more holistic hypothesis is instead “tissue-orientated”, and considers 
overall changes taking place at tissue and possibly at a systemic level as critical 
factors that contribute to the increased risk of cancer with aging. While this 
proposition has long been centred on the idea that the link between aging and 
cancer relates to a decreased immune-surveillance in older age, allowing for the 
immune-escape of putative cancer cells, during the last decade the role of age-
related, specific alterations in the tissue microenvironment is emerging has a major 
determinant in the pathogenesis of neoplastic disease.  
These two hypotheses, “cell-orientated” and “tissue-orientated”, need not to be 
mutually exclusive and may in fact complement each other towards our 
understanding of the origins of cancer, both in general terms and as it relates to the 
specifics of the links between cancer and aging. However, it is important to point out 
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that they are conceptually distinct and they often run in parallel, with little or no 
sharing of research approaches and scientific experience. There is  also little doubt 
that the “cell-orientated” hypothesis is still largely prevalent, although the more 
holistic approach is gaining ground.  
The studies presented in my thesis delve into the complex relationship between 
cancer and aging using analytical approaches shared with the field of regenerative 
medicine. We took advantage of a model of orthotopic cell transplantation to explore 
the basic question as to whether the contribution of aging to the risk of cancer is, at 
least in part, related to alterations in the tissue microenvironment. Previous 
investigations conducted by our research group had revealed that isolated normal 
hepatocytes form larger clones of daughter cells when transplanted into the liver of 
old animals as compared to those formed in young recipients. In a relatively simple 
experiment we then utilized a similar approach to transplant preneoplastic cells 
isolated from hepatic nodules into either young or old animals of a syngeneic strain. 
Results were striking: very limited expansion of transplanted nodular hepatocytes 
was observed in the liver of young animals, while the same cell preparations grew 
significantly upon injection into older hosts, with a few cases of progression to 
hepatocellular carcinoma (HCC).  
The relevance of these findings is twofold. Firstly, they clearly indicate that 
preneoplastic cell populations isolated from hepatic nodules are not endowed with 
any measurable degree of growth autonomy, in that they were unable to form 
nodules when transferred into the liver of young hosts. Thus, their focal growth is 
dependent on stimuli originating from the local microenvironment. In this respect 
they behave like normal hepatocytes. Secondly, it is evident from these results that 
the microenvironment of the aged liver is able to foster the growth of transplanted 
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syngeneic nodular hepatocytes, again reproducing analogous findings already 
obtained with normal cells. 
Having established this fundamental fact, it became important to explore possible 
biological and underlying molecular mechanisms explaining the growth-promoting 
nature of the aged liver microenvironment. To this end, intriguing insights came 
again from the field of regenerative medicine.  
Our research group is involved in the characterization of an experimental model of 
massive liver repopulation through hepatocyte transplantation. This approach was 
set up in our laboratory and is based on the administration of retrorsine (RS), a 
naturally occurring alkaloid, as a preconditioning treatment.  
Rat liver exposed to RS and then transplanted with isolated normal hepatocytes is 
entirely replaced by donor-derived cells within a few months. Importantly, 
transplanted nodular hepatocytes can also selectively expand in the RS-treated 
liver, rapidly evolving to HCC. Again, neither normal, nor nodular hepatocytes are 
able to proliferate when injected into the liver of untreated recipients, as already 
noted above. This pattern of findings is similar to that observed in the aged liver, 
although the magnitude of the observed phenomena is far greater following 
exposure to RS. Moreover, it is apparent from the foregoing discussion that the 
growth of normal and nodular hepatocytes is controlled by fundamentally similar 
biological mechanisms, such that carcinogenesis and liver repopulation represent in 
fact “two sides of the same coin”, as it has been proposed. 
Given the similarities of biological responses between the RS-treated and the aged 
liver, we then probed into possible cellular and molecular analogies shared by the 
two systems. Much to our surprise, it was found that exposure to RS is a powerful 
inducer of cell senescence in hepatocytes in vivo. As reported in the preceding 
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section of this report, several markers of cell senescence were expressed by RS-
exposed hepatocytes, including senescence-associated β-galactosidase (SA-β-gal), 
cell hypertrophy, a persistent block in the cell cycle coupled with activation of cell 
growth pathways. 
While cell senescence is primarily considered as an important biological barrier 
against the emergence of potentially neoplastic cells, it has now become clear that 
the presence of senescent cells can also foster neoplastic progression, possibly 
through effects related to the senescence-associated secretory phenotype (SASP). 
The latter includes a growing list of cytokines, growth factors and matrix-remodelling 
products which are released by senescent cells in the local microenvironment and 
exert their action through autocrine and/or paracrine mechanisms. A main 
component of SASP is IL-6, a pro-inflammatory cytokine which is also known for its 
important role in hepatocyte proliferation. Interestingly, IL-6 was found increased in 
the rat liver exposed to RS, suggesting that it might be involved in the stimulation of 
transplanted hepatocytes in this system.  
The picture emerging from these findings is that RS treatment, which sets the stage 
for the selective growth of both normal and nodular transplanted hepatocytes, 
leading to massive liver repopulation and emergence of HCC, respectively, is also 
associated with the induction of a senescent phenotype in resident hepatocytes.  
Such a senescence phenotype is commonly found in aged tissues including the 
liver, as also shown in our studies. This phenotype is likely to explain, at least in 
part, the similarities observed between the microenvironments of the aged liver and 
that of RS-exposed liver. 
The last section of this thesis describes studies aimed at reversing the RS-induced 
alterations in the liver microenvironment and, in doing so, at verifying whether this 
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would modulate the growth of preneoplastic lesions promoted by RS. Animals given 
the genotoxic agent diethylnitrosamine (DENA) followed by RS developed large 
hepatocyte nodules within a few months. However, the growth of preneoplastic 
nodules was significantly delayed in animals receiving hepatocyte transplantation 
following the DENA+RS regimen. These results represent a proof of principle that 
an altered microenvironment is indeed a powerful driving force in neoplastic 
progression; most importantly, they clearly indicate that strategies aimed at 
“normalizing” such an altered microenvironment might impact on the rate of 
progression of the neoplastic process. 
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2 Introduction 
 
 
2.1 Foreword 
This dissertation delves into the intriguing analogies between the relatively new and 
expanding field of regenerative medicine and the old, but still highly relevant field of 
neoplastic disease. One shared theme between these two fields that comes to 
mind, almost immediately, is stem cells: it goes without saying that stem cells 
represent the cornerstone of regenerative medicine, but they have also gained 
enormous attention and stimulated a very active debate within the cancer 
researcher’s community. However, stem cells are not the topic of this thesis. 
Rather, the studies presented here highlight common pathogenetic mechanisms 
rooted in the local microenvironment which appear to modulate both tissue repair 
and regeneration and the emergence of the neoplastic phenotype. A major finding 
of these studies is that cell senescence stands out as a dominant component of 
such a microenvironment. More specifically, the senescence-associated secretory 
phenotype, with its complex composition of inflammatory cytokines and growth 
factors, has the potential to impact on both tissue regeneration and carcinogenesis. 
The role of cell senescence is just beginning to be unraveled. However, it is already 
evident that this phenotype, far from being a merely passive end result of a cell life 
cycle, emerges as a new state of differentiation, which in turn can exert profound 
effects on chronic disease processes related to cell and tissue turnover.                                                            
This topic is explored using a novel experimental system that bridges regenerative 
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medicine and carcinogenesis: the retrorsine-based model for massive liver 
repopulation via hepatocyte transplantation; however, reference will be also made 
to normal physiological aging. The essential background information is provided in 
the following introductory sections. 
 
2.2 Cell Senescence 
According to Greek mythology, the Goddess Eos asked Zeus to grant immortality to 
the Trojan Tithonus, her mortal lover. But Eos had forgotten to ask for eternal youth, 
so Tithonus received the ‘‘gift” of immortality and continued to age, withering 
beyond recognition and begging eternally for death. 
In similar fashion, improved sanitation and better nutrition, with the contribution of 
modern medicine, have increased the life expectancy of individuals in the 
developed world, but this has not been matched by equal progress in our ability to 
alleviate the ill health associated with increased age. Thus, aging has become a 
major research topic over the past few decades1. 
Interest in the role of aging within the sphere of hepatology has increased, 
especially with the recent recognition of the importance of age in determining the 
clinical outcome in common livers diseases such as chronic hepatitis C virus 
infection2 and the influence of donor age on graft survival after liver transplantation3. 
It is also well established that the ability of the liver to withstand the consequences 
of injury falls with each decade. Thus, liver-related death in older persons is 
increased substantially when compared to younger individuals with the same 
condition4. The cellular and sub-cellular changes that underlie this predisposition 
are the subject of much scrutiny. There is undisputable evidence that the aging 
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process takes place, at least in part, at the cellular level and that these changes can 
be stimulated ‘prematurely’ if affected by chronic inflammation. Within this context, 
the role of cell senescence is receiving increasing attention5. 
Cellular senescence was formally described more than four decades ago when 
Hayflick and colleagues showed that normal cells had a limited ability to proliferate 
in culture6. This fundamental finding carried two main conceptual implications. 
Given the fact that many cancer cells proliferate indefinitely in culture, the 
senescence response was interpreted as one mechanism that protected tissues 
and organisms from cancer. On the other hand, considering that the ability to 
perform tissue repair deteriorates with age, cellular senescence was seen as the 
possible basis for the aging process at organ and organismal levels, as exemplified 
by the loss of regenerative capacity of tissues in vivo.  
The idea that a biological process such as cellular senescence can be both 
beneficial (tumor suppressive) and deleterious (limit tissue renewal) is consistent 
with a significant evolutionary theory of aging named antagonistic pleiotropy.7 
In agreement with the antagonistic  pleiotropic  theory of aging, natural selection 
has favored genes providing advantages to the organism during the reproductive 
years, at the expenses of deterioration in the distant future. The ‘disposable soma’ 
theory expresses this as a life-history strategy in which somatic maintenance is 
below the level required to prevent aging, hence allowing increased prompt fertility.  
However, the interpretation of cell senescence within the scheme of antagonistic 
pleiotropy is not universally accepted. Recently, Blagosklonny et al. have argued 
that cell senescence is the end result of two opposing signals: one that reads for 
cell growth and the other imposing a persistent block in the cell cycle. As such, it is 
perfectly functional to the biology of both young and older tissues and organisms. 
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Furthermore, the discovery and characterization of the SASP has clearly indicated 
that cell senescence leads to profound changes in the tissue microenvironment, 
potentially modulating tissue repair and regeneration as well as the progression of 
chronic disease processes such as neoplasia. 
 
2.2.1  Characteristics of senescent cells 
Cellular senescence is an important stress related response to injury that induces 
stable cell-cycle arrest with important implications for the survival and function of the 
cell, the organ, and the organism. 
Cellular senescence is confined to mitotically capable cells. Although these cells 
can proliferate, they can also spend long periods in a reversibly switched off mode 
named quiescence or G0. Quiescent cells resume division in response to 
appropriate signals, comprising the need for tissue repair or regeneration. On the 
other hand, post-mitotic cells permanently lose the ability to proliferate owing to 
differentiation8. Mitotic cells can senesce when they come across potentially 
oncogenic circumstances. When this happens, the cells cease proliferation (known 
as growth arrest), and cannot be reversed by known physiological stimuli. They 
frequently become resistant to cell-death stimuli (apoptosis resistance) and they 
acquire widespread changes in gene expression. Together, these features comprise 
the senescent phenotype. 
One of the main characteristics of cellular senescence is an inability to progress 
through the cell cycle. Senescent cells arrest growth, usually with a DNA content 
that is typical of the G1 phase, yet they remain viable with low levels of cellular 
metabolism9-12. Once arrested, initiation of DNA replication is unsuccessful 
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regardless of ideal growth conditions. This replication failure is in fact  induced by 
an activated DNA damage response (see next section).  
 As opposed to quiescence, the senescence growth arrest is essentially permanent 
(at least in the absence of experimental manipulation), since senescent cells cannot 
be induced to resume the cell cycle by known physiological stimuli. 
2.2.2 The DNA damage response and cell senescence 
The senescence response is caused by many potentially oncogenic signals, 
comprising dysfunctional telomeres, DNA damage and strong mitogenic stimuli 
including those transmitted by some oncogenes. Many of these signals, directly or 
indirectly cause DNA damage and activate the DNA damage response (DDR) 5,13.  
Historically, telomere shortening was suggested to be the main mechanism causing 
replicative cellular senescence (Hayflick’s limit). The inability of standard DNA 
polymerases to fully replicate linear DNA molecules causes the estimated loss of 
around 50 to 200 base pairs during each cycle of replication at the 5′ end of the 
lagging strand. Therefore, the end replication problem leads to gradual shortening 
of chromosomes at every DNA replication round and subsequent cell division, 
eventually leading to DDR activation at critically short telomeres. Yet, the precise 
critical length of such dysfunctional telomeres is still unclear14. 
The DDR is mediated by DNA damage protein sensors such as the MRE-RAD50-
NBS-1 (MRN) complex, which triggers the switch of a signal transduction system 
comprising the protein kinases ATM (ataxia telangiectasia mutated), ATR (ATM and 
Rad3-related), CHK1 and CHK2 (checkpoint kinase 1 and 2). According to the 
prevailing view, the DDR then activates p53, which promotes either apoptosis or 
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senescence via transactivation of its downstream targets, including the cyclin 
dependent kinase inhibitor, p21 Cip1 15.  
Figure 1: DNA damage response: causes-mechanisms-consequences. 
 
Cells that undergo senescence due to continuous DDR signaling harbor persistent 
nuclear foci, termed DNA segments with chromatin alterations reinforcing 
senescence (DNA-SCARS)16. These foci contain activated DDR proteins, including 
phospho-ATM and phosphorylated ATM/ataxia telangiectasia and Rad3 related 
(ATR) substrates9,17-19, and are distinguishable from transient damage foci16 . 
The DDR might lead to senescence in two ways. First, it can switch on p53, which 
inhibits cell growth via p21CIP1/WAF1 20. 
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It has been suggested that at low levels of damage, the DDR is transient, while high 
levels would cause chronic DDR signaling and p53 activation, which would then 
maintain a senescence growth arrest 20-21. 
Second, the DDR activates a subset of the senescence-associated secretory 
phenotype (SASP), independent of p53 activity; accordingly, loss of p53 function 
amplifies the SASP, suggesting that p53 restrains this phenotype22. 
 
2.2.3 Factors inducing cellular senescence 
Besides the continuous passaging of cells in culture described by Hayflick, cellular 
senescence can be induced in vitro by multiple stimuli (figure 2). Methods of 
induction include: 
2.2.3.1 DNA damage by genotoxic agents  
Genotoxic agents such as radiation (X or γ-rays, UV) or DNA-interacting drugs (e.g. 
bleomycin, doxorubicin, mitomycin)23-26, cause DNA double-strand breaks (DSBs). 
Short or dysfunctional telomeres are also thought to form a structure that resembles 
DSBs27-31. The response of the cell to such damage is the assembly of large 
protection complexes around the breaks that stabilize the structure and prepare for 
potential repair32-35. 
DSB is a type of DNA damage which occurs when two nearby complementary 
strands of the double helix of DNA get damaged simultaneously. DSB is the most 
dangerous type of DNA damage, because it has been suggested that a single 
unrepaired DSB is sufficient for the initiation of the cell death procedure36-37.  
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The factors leading to the formation of DSBs comprise also endogenous factors, 
that are associated  with  physiological  processes  that take place  in  the  cell, and 
the exogenous ones38-39 in living cells. DNA is constantly subject to a process of 
oxidative damage by oxygen free radicals (reactive oxygen species—ROS)  that are 
produced inside  the cell as a consequence of metabolic processes40. 
It has been estimated that in a single cell cycle at least 5000 single-stranded DNA 
breaks can occur as a result of ROS production. About 1% of these DNA lesions 
deteriorate into DSBs, mainly during DNA replication, whereas the remaining  99% 
are fixed. Hence, during the cell cycle in a single nucleus, around 50 “endogenous” 
DSBs are produced. Accumulation of unrepaired DNA damage induced by ROS 
leads to cellular aging and  might be accountable for the initiation of neoplastic  
transformation39-41. Is it accepted that the main cellular response to DSBs include 
cell-cycle regulation, DSB repair, transcriptional activation of relevant genes 
(including those associated with repair), increase in cellular levels of 
deoxyribonucleotides and in certain cells induction of apoptosis42-43. 
In eukaryotic cells, the effective repair of DSBs is essential for survival. Two major 
pathways have evolved to counteract these breaks, homologous recombination 
(HR), and non-homologous end-joining (NHEJ)44. The mechanism of HR relates to 
the use the genetic information from a corresponding undamaged region present on 
the second DNA molecule or homologous chromosomes and hence is active mainly 
during S and G2 phases of cell cycle. NHEJ is based on a direct ligation of the two 
ends of damaged DNA molecules and repairs DSBs mainly in G1 phase45. 
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2.2.3.1.1 H2AX, ATM and SCARS 
H2AX phosphorylation is an important step in the DDR, having a role in signaling 
and initiating the repair of DSBs46. 
It was reported several years ago, that in mammalian cells the phosphorylation of 
the subtype of histone H2A, called H2AX, in the position of Ser139 occurs in 
response to DSB formation. The phosphorylated form of H2AX is referred to as γ-
H2AX47-48. Histone H2AX is a substrate of several phosphoinositide 3-kinase-related 
protein kinases (PIKKs), such as ATM (ataxia telangiectasia mutated), ATR (ATM 
and Rad3-related), or DNA-dependent protein kinase (DNA-PK). These processes 
are aimed to stop the progression of the cell cycle and to activate proteins 
responsible for DNA repair49-51. Several lines of evidence suggest the critical role of 
H2AX phosphorylation at DSB sites for nuclear foci formation and induction of DSB 
repair: 
 H2AX-knockout cells manifested impaired recruitment of NBS1, 53BP1, and 
BRCA1 to irradiation-induced foci 52. 
 Both H2AX+/− and H2AX−/− mouse thymocytes show an increase in 
chromosomal aberrations53-55. 
 Mouse embryonic stem (ES) cells deficient in H2AXphosphorylation have 
alterations in efficiency of DNA repair by NHEJ or HR. As a result of these 
defects in DNA damage repair, such cells have increased sensitivity to DNA 
damage54-58. 
 H2AX knock-out mice show male-specific infertility and reduced levels of 
secondary immunoglobulin isotypes, suggesting defects in class switch 
recombination (CSR)52. It was shown that efficient resolution of DSBs 
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induced during CSR in lymphocytes requires H2AX54-56, and its absence is 
associated with chromosome abnormalities involving the immunoglobulin 
locus54. 
Moreover, this specific “anchoring” function of γ-H2AX at sites containing DSBs, 
would inhibit the irreversible disassociation of broken DNA ends and promote 
chromatin compaction to facilitate error-free repair, thereby suppressing 
inappropriate translocations of chromatin fragments. In this way, γ-H2AX-mediated 
mechanisms prevent DNA ends from drifting apart, inappropriate rejoining of 
chromatin fragments, resulting in genetic translocations and other abnormalities.44 
The contribution of γ-H2AX to signaling is thought to lie in the ability of this 
chromatin modification to increase DNA accessibility, leading to the recruitment and 
accumulation of specific DDR proteins at DNA ends. Discrete nuclear foci that form 
as a result of H2AX phosphorylation are now widely used as a quantitative marker 
of individual DSBs59.  Studies have found that each DSB corresponds to one γ- 
H2AX focus but the reverse is not applicable as γ-H2AX may persist even after 
DSBs are rejoined60-61. High numbers of small foci are formed at the early stages of 
the DDR, decreasing in number and increasing in size as the DDR progresses62 .                
The loss of γ-H2AX at DSB sites is thought to reflect the completion of repair of 
DNA at break sites63. It is unclear when a DSB is completely repaired. Some studies 
suggest that this is on rejoining of both DNA strands whereas others propose that 
chromatin has to be returned to its original state of compaction before a DSB is truly 
repaired64-65. 
One of the most critical kinase-activating cell cycle checkpoints following DNA 
damage is ATM. Mutations in the ATM gene results in the genomic instability and 
cancer predisposition syndrome Ataxia-Telangiectasia (AT) syndrome.  In response 
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to DSBs, ATM phosphorylates many cell cycle checkpoint-related factors such as 
p53, Chk2 ,SMC1 and NBS166. 
ATM kinase is considered as a major physiological mediator of H2AX 
phosphorylation in response to DSB formation50-51. ATM is activated by its auto 
phosphorylation at Ser1981 position, which leads to dissociation of the inactive ATM 
dimers into single protein molecules with increased kinase activity47-48.  A tri-protein 
complex called MRN complex (MRE11-RAD50-NBS1) recognizes DNA damage, 
recruits ATM to the site of damage and also functions in targeting ATM to initiate 
phosphorylation of the respective substrates67-68.  It is also reported that ATM 
activation requires prior ATM acetylation, mediated by Tip60 histone 
acetyltransferase68-69. 
When DNA lesions are repairable, DNA damage foci are transient. They typically 
resolve within 24 hours, during which time cells transiently arrest growth, 
presumably to allow time for repair15. However, severe or irreparable DNA damage, 
such as complex breaks or uncapped telomeres, causes many cells to senesce with 
persistent DNA damage foci, constitutive DDR signaling and chronic p53 activation. 
These persistent changes precede establishment of senescence-associated 
phenotypes, including growth arrest9-16-20 and SASP70 . 
It is not known whether the persistent foci associated with senescence contain 
components that are distinct from those in transient foci. In addition, while the 
persistent foci clearly contain active DDR components, it is not known whether 
these structures maintain the DDR activity that is required for the senescence-
associated growth arrest or cytokine secretion. Because markers of persistent foci 
are recruited to locally modified chromatin, these persistent foci are termed “DNA 
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segments with chromatin alterations reinforcing senescence” or DNA–SCARS, that 
are relatively stable structures distinct from transient damage foci and functionally 
important for maintaining the senescence-associated growth arrest and secretion of 
IL-615. 
Individual persistent foci were stable for several hours in living cells, and, in fixed 
senescent cells, were detected for days and weeks after their formation. The repair 
system HR and NHEJ are likely either inactive or incapable of resolving these foci 
after 48h. Formation of DNA-SCARS was accelerated in cells that are deficient in 
certain DNA repair proteins supporting the idea that ineffective or defective repair 
initiates the formation of these structures. DNA –SCARS include also foci generated 
by senescence-inducing DNA damage inflicted by H2O2 or oncogenic RAS. The 
formation of DNA-SCARS is a robust phenomenon that is conserved between 
mouse and human, as are many other features of cellular senescence71 , that occur 
in culture and in vivo . 
2.2.3.2 DNA damage by oxidative stress 
Oxidative stress results in formation/accumulation of reactive oxygen species 
(ROS)56,72-73. The generation of reactive oxygen species (ROS) and free radicals is 
considered as one of the mechanisms of aging, acting through oxidative stress 
inflicted on DNA and other cellular constituents74. ROS can also activate 
transcription of genes implicated in inflammatory and other chronic disease- 
processes75.  According to recent data oxygen radicals can also directly participate 
in the induction of cell senescence11 . 
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2.2.3.3 DNA damage by oncogenic or hyper-proliferative signals 
Oncogenes are mutant versions of normal genes that have the potential to 
transform cells in conjunction with additional events. Normal cells respond to the 
activation of some oncogenes by eliciting a senescent phenotype76. 
Because oncogenes that induce senescence stimulate cell division, the senescent 
response could be aimed at counteracting excessive activation of the cell cycle, 
which would put cells at risk of oncogenic transformation5. 
The pathways mediating ‘oncogene-induced senescence’ (OIS) are not completely 
elucidated but, the proliferative arrest involves activation of both Rb and p53 
pathways77. The normal endogenous expression level of an activated oncogene is 
not sufficient to trigger senescence . 
OIS is often accompanied by the upregulation of the CDK inhibitors p15INK4B 
p16INK4A, and  p21 CIP1 78. 
 
 
Figure 2: stimuli inducing cellular senescence 
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2.2.4 The secretory phenotype of senescent cells 
Cells undergo cellular “reprogramming” during senescence, result in permanent 
growth arrest and in changed morphology and function5.  
A significant trait of this reprogramming is the gain of a secretory phenotype, which 
involves a striking enhancement in the secretion of growth factors and cytokines by 
senescent cells, hence exerting a broad range of effects on the local tissue 
environment. This secretory pattern has been referred to as the “senescence-
associated secretory phenotype” (SASP)22, and includes changes in the secreted 
levels of >40 factors involved in the intercellular signaling. For the induction of 
several of these SASP factors are required persistent DNA damage. 
A significant features of the SASP is that it occurs in vivo and remains conserved in 
both human and mouse cells79 , and in numerous proliferative cell types (fibroblasts, 
epithelial cells, endothelial cells, astrocytes, etc..)20,80-81. SASP factors can globally 
be divided into the following major categories: soluble signaling factors (interleukins, 
chemokines, and growth factors), secreted proteases, and secreted insoluble 
components. SASP proteases can have three main effects:  
 shedding of membrane-associated proteins resulting in soluble forms of 
membrane-bound receptors 
  cleavage/degradation of signaling molecules 
  degradation or processing of the extracellular matrix. 
 These roles provide potent mechanisms by which senescent cells can modify the 
tissue microenvironment82.  
Proteins that are known to stimulate inflammation, including IL-6, IL-8, IL-1, 
granulocyte macrophage colony stimulating factor (GM-CSF), growth regulated 
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oncogene (GRO)α, monocyte chemotactic protein (MCP)-2, MCP-3, MMP-1, MMP-
3, and many of the Insulin-like growth factor (IGF)-binding proteins20,83 are among 
the most robustly induced and secreted factors in the SASP response.  
The SASP inflammatory cytokines are of particular interest because they can play a 
role in many age-related pathologies84. In addition to being inflammatory mediators, 
IL-6 and IL-8 were recently shown to belong to a minor number of secreted factors 
which also reinforce the senescence growth arrest via autocrine and paracrine 
mechanisms85-89.  
The mechanisms that initiate and maintain the SASP are unclear. IL-1α and IL-β are 
minor SASP components which, compared to IL-6 and IL-8, are secreted at low 
levels90. IL-1 (α/β forms) is a multifunctional cytokine that regulates inflammatory 
and immune responses mainly by originating a signal transduction cascade which 
lastly induces IL-6 and IL-8 expression91. Recombinant IL-1α and IL-1β interact with 
the same receptor (IL-1R) and mediate similar biological effects. However, IL-1β is 
active only as a mature secreted form, while IL-1α is rarely secreted at high levels 
and produces effects either intracellularly or as a cell surface-bound protein. In 
addition, IL-1α, differently from IL-1β, can function both as an uncleaved precursor 
protein (pIL-1α) or as a cleaved protein92. Once IL-1R binds its receptor, IL-1 
initiates the formation of a complex containing IL-1R and its coreceptor (IL-1RAcP). 
This complex triggers a series of cytoplasmic events that ultimately activate the 
transcription factor NF-KB93. NF-kB then transactivates numerous genes, including 
those encoding IL-6 and IL-894. 
The most prominent cytokine of the SASP is interleukin (IL)-6, a pleiotropic pro-
inflammatory cytokine22. IL-6 secretion has been shown to increase markedly after 
 21   
 
DNA damage- and oncogene-induced senescence of mouse and human 
keratinocytes, melanocytes, monocytes, fibroblasts and epithelial cells86. 
The senescence response, SASP in particular, may reduce health by stimulating 
both the low level inflammation associated with aging as well as the development of 
specific age-related diseases95.  
Interestingly, this secretory phenotype seems to behave as a double edged sword 
regarding tumor initiation and maintenance: 
a. On the one hand, it has been shown that the SASP can have pro-
tumorigenic effects; for instance, it has been shown that senescent 
mesenchymal cells have been documented to increase the tumorigenicity 
of nearby breast cancer cells96. Similarly, it has been proposed that loss 
of proliferative competition of non-transformed, senescent cells can 
accelerate progression of leukemic cells during aging97. It remains to be 
seen whether aberrant secretion of cytokines and growth factors by the 
SASP can accelerate this process in aged and chronically damaged 
organ systems. 
b. Conversely to its pro-tumorigenic properties, the SASP presents anti-
tumor effects. It has been reported that in a mosaic liver cancer mouse 
model the activation of p53 induced senescence, an up-regulation of 
inflammatory cytokines, and stimulation of innate immune responses 
causing tumor cell clearance98. Additionally, more studies reported that 
components of the SASP can stabilize the senescence cell cycle arrest 
via an autoregulatory feedback mechanism or it can induce apoptosis of 
tumor cells85-86,88. 
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Many of SASP factors can contribute to normal tissue repair: IL-6, IL-8, MMP, 
growth factors and protease S participate in wound healing, attractants for immune 
cells kill pathogens, proteins mobilize stem or progenitor cells, thus, another 
function is to communicate cellular damage/dysfunction to the surrounding tissue 
and if needed, stimulate repair. 
Besides its influence on tumorigenesis, the SASP could also affect tissue aging. 
Experiments on aging telomere dysfunction in mice show direct proof for an in vivo 
activation of the SASP99.  
Interestingly, in vivo SASP provoked alterations in stem cell differentiation that are 
also characteristic signs of human aging. Tissue specific or adult stem cells, which 
are capable to self-renewal and differentiation, are essential for the normal 
homeostatic maintenance and regenerative repair of tissues through the lifetime of 
an organism. 
The self–renewal ability of stem cells is known to decline with advancing age, 
eventually leading to the accumulation of unrepaired, damaged tissues in old 
organisms. By limiting cell proliferation, senescence in stem cells is hypothesized to 
contribute to aging by reducing the renewal capacity of these cells. 
It remains to be determined whether stem cells undergo senescence during aging 
and whether inhibition of senescence may slow aging. 
The reason why senescent cells are found with increasing frequency in older 
tissues is still unclear100-102. 
It is not known whether this rise is caused by increased generation, decreased 
elimination, or both an in vivo activation of the SASP in response to telomere 
dysfunction. One theory could be that the aging immune system, which shows both 
decrements and derangements in function, becomes less capable of clearing 
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senescent cells103.  Furthermore, the production of senescent cells may increment 
with age due to an age-dependent enhancement in tissue damage, e.g. by 
increasing oxidative stress caused by progressively more damaged and therefore 
less functional mitochondria104. Is also possible that a constant fraction of senescent 
cells escape immune clearance such that they steadily accumulate with advancing 
age. Whatever the case, the chronic presence of cells which secrete various 
proteins with significant biological activities may be predicted to considerably modify  
tissue structure and cause a  decline in tissue repair and regeneration. 
 
2.2.5 Biomarkers of cellular senescence 
Cellular senescence has been well described in a wide variety of cells tissues in vivo 
and in vitro. Indeed, in vivo senescent cells are found in human, rodent vascular 
endothelial and smooth muscle cells, animal skeletal muscle, fat tissue and liver105-
106. Several cellular markers are used to identify senescent cells in vitro and in vivo 
including:  
 
a. Cell enlargement. Flatness and enlarged cell shape of senescent cells  
has been previously reported in the seminal work of Hayﬂick and 
Moorhead (1961), who discovered the phenomenon of replicative 
senescence of human fibroblasts.  An obvious marker for senescent cells 
is the lack of DNA replication, which is typically detected by the 
incorporation of 5-bromodeoxyuridine or 3H-thymidine, or by 
immunostaining for proteins such as PCNA and Ki-67. Unfortunately, 
 24   
 
these markers do not discriminate between senescent cells and quiescent 
or differentiated post-mitotic cells. 
 
b. SA-β-gal activity. Since it was first reported107 , SA-β-gal activity has 
been the most widely utilized biomarker in detecting senescent cells 
because of the simplicity of the assay method and its apparent specificity 
for senescent cells. This  histochemical stain identifies a variety of cell 
types at replicative senescence in vitro . The precise function of  SA-β-gal 
in senescence remains unknown, but it is thought that it becomes 
elevated in senescent cells due to the  expansion of lysosomes, which 
contain β-galactosidase as a lysosomal enzyme107. The technique derives 
from an observation that β-galactosidase activity measured at pH 6.0 
selectively stains senescent cells, while the same procedure conducted at 
pH 4.0 uniformly stains cultures for lysosomal β-galactosidase. The pH 
6.0 activity, now known as senescence-associated β-galactosidase, is 
extensively utilized to identify the presence of senescent cells in vitro.  
SA-β-gal activity has been detected in organs of old individuals and 
animals, suggesting that cellular senescence is an aging trait of 
organisms and that senescent cells accumulate with age in various 
tissues108.  
The presence of the SA-β-gal biomarker is independent of DNA synthesis 
and generally distinguishes senescent cells from quiescent cells. SA-β-
Gal activity is commonly accepted as a marker of senescence both in 
vitro and in vivo, although there is evidence for a positive SA-β-Gal  
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reaction in settings of cellular stress that are independent  of senescence, 
including serum withdrawal or high confluence in cell culture.  
A pathogenetic role of SA-β-Gal in cell senescence is unknown. A 
possibility is that SA-β-Gal activity is correlated to the increased 
lysosomal content of senescent cells, which allows the detection of the 
enzyme activity at suboptimal pH of 6.0 (the optimal pH being at 4.0)107. 
 
c. DNA damage foci. The use of DNA damage foci has been suggested as 
a marker for the detection of senescent cells31-109. Both DNA double 
strand breaks and telomere uncapping16 are able to induce a DNA 
damage response. This reaction is characterized by activation of 
ATM/ATR which is recruited to the site of damage, causing the 
phosphorylation of Ser-139 of histone H2AX molecules (γ-H2AX) next to 
the site of DNA damage. The phosphorylation of histone H2AX facilitates 
the focal assembly of checkpoint and DNA repair factors such as 53BP1, 
MDC1/NFBD1 and NBS1, and also mediates the activation by 
phosphorylation of Chk1 and Chk2, which converge the signal on 
p53/p2112. 
 
d. Inhibitors of cell cycle progression. The cyclin-dependent kinase 
inhibitor p16 is an important regulator of senescence and is expressed by 
many senescent cells70,110. Investigation of the signaling pathways 
leading to OIS has shown that two main pathways are involved in cell 
cycle arrest, p16INK4a–RB (retinoblastoma) and ARF–p53111. These two 
pathways are thought to be crucial for tumor suppression and are often 
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mutated in tumors112-113. Among the important components of these 
pathways are cyclin-dependent kinase inhibitors (CDKIs). CDKIs inhibit 
critical cell cycle-regulatory phosphorylation events, such as those that 
inactivate the growth suppressive activity of pRB112. One such CDKI, 
p21CIP1/WAF1 (CDKN1A), is a direct target of p53 transactivation, generally 
in response to genomic damage, and is crucial for establishing and 
maintaining the p53-mediated senescence growth arrest 114-115..  Another 
CDKI, p16INK4a (CDKN2A), is a tumor suppressor in its own right, can be 
induced by stress that does not entail DNA damage116-117, and acts 
upstream of pRB to establish the pRB-regulated growth arrest118-120. 
 
There are also additional markers of senescence that have been proposed, whose 
precise role is currently unclear. For example, an important feature of the aging 
phenotype is reduced capacity to activate autophagy, a highly conserved 
mechanism and very efficient cellular response to stress. However, an increase of 
autophagy activity during brain aging has been recently shown121 and other groups 
have reported that autophagy/mTOR activity may be involved in the transition to the 
OIS state 122.  Although the latter observations indicate a similar role of autophagy 
and senescence in suppressing cancer development, the role of 
autophagy/senescence transition urgently needs to be verified in other cellular 
systems.  
The information that is available regarding the different pathways implicated in OIS 
is being exploited to obtain new senescence markers. For example, modifications to 
protein-degradation pathways (through the proteasome and the lysosome), the 
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epigenetic status of the chromatin, cell-cycle arrest and others are being 
investigated123. 
Another possibility is the identification of soluble factors released by senescent cells 
that could, for example, be measured in body fluids such us blood, urine or sputum. 
Thanks to the analysis of the gene-expression profile of senescent cells, it has 
become clear that senescent cells have characteristic alterations in secreted growth 
factors, inflammatory cytokines, extracellular-matrix components and matrix-
degrading enzymes, some of which could be easily detected124. 
 
2.2.6 Cellular Senescence and Inflammation 
The link between inflammation and cellular senescence was initially proposed 
following experimental reports on the gene expression profiles of senescent cells. 
These findings demonstrate that senescence is connected with gene expression 
patterns analogously to those observed in inflammatory responses and wound 
healing processes. Enhanced expression of inflammation associated genes, 
comprising the chemokines monocyte chemotactic protein-1 (MCP-1) and Gro-α, 
cytokines IL-15 and IL-1β, Toll-like receptor 4 (TLR4) and intercellular adhesion 
molecule-1 (ICAM-1), was originally observed in senescent human dermal 
fibroblasts125-126 and subsequently confirmed in other cell types, such as epithelial 
cells. 
Chronic inflammation is linked to numerous age-related pathophysiologic processes 
and diseases, such as cancer, diabetes, Alzheimer’s disease, atherosclerosis, 
osteoarthritis etc.127-128. Chronic inflammation is also associated with normal aging. 
For instance there is an average 2-4 fold enhancement in serum levels of pro-
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inflammatory signals (e.g. interleukin (IL)-6 and tumor necrosis factor (TNF)-α in 
aged individuals (>50 years of age), compared to younger individuals129-130. 
Furthermore, individuals who experience unusually healthy aging (for instance, 
healthy centenarians) typically have a lower inflammatory profile than frail 
centenarians131. The inflammatory status of cellular senescence might have 
opposite effects on neoplastic disease. Secretion of inflammatory cytokines and 
chemokines is crucial for the induction and maintenance of the senescence 
phenotype, which prevents premalignant tumor cells from progressing into a 
malignant state. Meanwhile, these inflammatory cytokines and chemokines 
produced by the senescent cells also create a cancer-inducing microenvironment 
for their neighboring tumor cells. Consequently, the net effect of the inflammatory 
state of senescence on the initiation of neoplastic disease significantly depends on 
the tissue environment, the genetic makeup of the tumor cells as well as the stromal 
cells, and the extracellular signals occurring in the tumor microenvironment132.                                                                                                                   
Inflammation is necessary to contrast damaging agents and is essential for survival, 
mainly to deal with acute inflammation during our reproductive years. But chronic 
exposure to a wide range of antigens, particularly to some viruses such as 
cytomegalovirus, a longer exposure than that predicted by evolution, induces a 
chronic low-grade inflammatory status that contributes to age-associated morbidity 
and mortality136.This condition is defined as “inflammaging”133. 
“Inflamm-aging” indicates the up-regulation of inflammatory cytokines over the 
course of the aging process, and the connected damage and chronic diseases.   
For the immune system, a typical consequence of aging is the progressive filling of 
the immunological system by activated lymphocytes, macrophages, and dendritic 
cells in response to chronic stress stimuli either from pathological or physiological 
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antigens and toxins134. Therefore, the state of inflammaging causes a constant mild 
antigenic challenge leading to a pro-inflammatory condition linked to the progressive 
stimulation of the immune system and other organismal systems135-138. Overall, 
immunosenescence can be referred as the proof that the beneficial effects of the 
immune system, aimed at the neutralization of harmful agents early in life, become 
detrimental as life progresses, as if evolution did not take into account old age134 . 
This viewpoint is consistent with basic assumptions of evolutionarily antagonistic 
pleiotropy theory7 in regard to aging, which suggests that a compromise between 
early beneficial effects and late negative outcomes can occur at the genetic and 
molecular level (Fig. 3). 
 
 
Fig. 3: Consequences of an inflammatory responses, a compromise in evolution: beneficial effects in 
early age and late negative outcomes. 
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2.2.7 Cellular senescence and aging. 
The first studies of cellular senescence in vivo showed that the number of 
senescent cells increase with age81,105,107. The increase in senescent cells occurs 
primarily in tissues which have mitotically competent cells, and it is now reported in 
many rodent and human tissues. Furthermore, senescent cells have been identified 
in tissues of several age-related pathologies such as atherosclerosis and 
osteoarthritis81,111. 
Studies suggest two mechanisms by which cellular senescence might actively 
induce aging and age-related pathology. 
First, the majority of adult stem cells are capable of undergoing senescence, and 
cellular senescence might account at least in part for the age-related diminishing 
number or function of certain stem cells in adult organisms139-142. 
Therefore, an accumulation of senescent stem cells may contribute to the reduced 
in tissue repair and regeneration that is hallmark of aging organisms. 
Second, the senescence-associated secretory phenotype (SASP) referred to above 
comprises factors that control many vital processes within tissues and organs, 
including cell growth, motility and differentiation, as well as tissue structure and 
vascularization. This feature of the SASP is important because a common trait of 
aging tissues is low-level chronic inflammation; moreover, it is well documented that 
inflammation causes or contributes to virtually every major age-related disease143-
144. It is then possible that senescent cells are a source of “sterile” inflammation that 
is hallmark of aging tissues and driver of multiple age-related pathologies. 
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2.3 Aging 
Aging is a persistent process that affects all cells, tissues, organs and organisms, 
reducing homeostasis and enhancing organism vulnerability145.  Aging progression 
leads to a decreased response to environmental stimuli, and is associated with an 
increased predisposition to illness146-147. Hence, mortality due to all causes 
increases exponentially with aging. 
The comparison of the mortality rate in developed countries among individuals over 
65 years, versus people in the age range between 25 and 44 years, shows an 
increase of 100-fold for stroke, and chronic lung disease, 92-fold for heart disease, 
89-fold for pneumonia & influenza and 43-fold for cancer 148.  
Aging can be defined as a continuous regression of tissue function that ultimately 
results in organ failure. Such functional decline can result from the loss or reduced 
function of post-mitotic cells or from failure to replace such cells by a malfunctioning 
ability of (stem) cells to carry out replication and cell divisions. Aging is not a 
disease, and the biology of aging, which varies between individuals, is best 
understood in the context of evolution149. On the cellular level, aging is thought to be 
caused by the accumulation of damage, induction of senescence, and loss of 
replicative capability. Nonetheless, aging takes place at different levels: the cellular, 
the organic specific, and at the level of the organism as a whole150. 
An essential mechanisms of aging is based on the production of reactive oxygen 
species (ROS) and free radicals74 . 
ROS and free radicals can be produced by environmental stimuli or can originate 
from intrinsic cellular causes as a consequence of cellular respiration, referred as 
oxidative stress. ROS mediates transcription of genes implicated in inflammatory 
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and other disease-associated processes, or  can cause damage to DNA and protein 
species75. Preventing oxidative stress is therefore an important factor to slow down 
the aging process. 
Genome instability is an important factor of aging in all eukaryotes. How age related 
genome instability occurs remains unclear151. 
The free radical theory of aging makes  oxidative damage to DNA and other cellular 
constituents a major factor in aging. Studies in the model organism Saccharomyces 
cerevisiae (budding yeast) and in higher eukaryotes suggest that growth signaling 
also influences aging and age-related diseases -such as cancer and 
neurodegeneration- by inducing DNA replication stress, which causes DNA 
damage. Replication stress, which is not considered as a factor in aging, may be 
enhanced by ROS that signal growth. 
Numerous potential mechanisms, often overlapping, have been proposed to explain 
age-dependent genome instability. These include the accumulation of oxidative 
damage to DNA, defects in mitochondrial function that promote oxidative stress and 
damage to DNA and other cellular components, mutations in proteins necessary for 
efficient DNA replication, DNA repair and checkpoints, telomere dysfunction and 
epigenetic effects on DNA repair and other genome maintenance programs. 
Although many of these mechanisms are likely to contribute to aging in a variety of 
eukaryotes, the specific contributions of each and their relative weight remain 
unclear.  
There is convincing evidence now that in all eukaryotes, aging is regulated by 
conserved insulin/insulin-like growth factor (I-(IFG-1)) pathways and growth-
signaling pathways regulated by the Target of Rapamycin (TOR) family of protein 
kinases152. In general, in experiments where these pathways are up-regulated aging 
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is promoted, whereas by down regulating these pathways through such as 
mutational inactivation extend life span and mitigate age-related pathologies. Down 
regulation of these pathways often leads to a reduction in oxidative stress and 
oxidative damage to DNA and other cellular components. 
It is documented that key mechanisms of both aging and cancer are linked via 
endogenous stress-induced DNA damage caused by reactive oxygen species. 
These include oxidative nuclear and mitochondrial DNA damage and repair, 
telomere shortening and telomere-driven cellular senescence153. 
2.2.1. Aging and cancer  
The incidence of malignant tumors is proportional to the increase of age in both 
animals and humans154-158. Three main hypotheses have been suggested to clarify 
the connection between cancer and age. The first proposes that this link is a 
consequence of the duration of carcinogenesis. In other words, the high prevalence 
of cancer in older individuals simply reflects a more prolonged exposure to 
carcinogens159. The second hypothesis supports the idea that age-related 
progressive changes in the internal milieu of the organism might provide an 
increasingly favorable environment for the initiation of new neoplasms and the 
proliferation of already occurring but latent malignant cells154,158,160-161. 
Frequent age related changes in tissue milieu comprise:  
• An increasing proportion of senescent fibroblast cells that support a 
proteolytic microenvironment facilitating the growth of the transformed cells162. 
• Inefficiency of aerobic pathways163 that are partially compensated by 
increased glycolysis. 
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• Local and systemic immune-deficits164 that can maintain a tissue 
microenvironment that also favours survival of transformed cells. 
• Dysfunctional cell-death programs in old age165 that would be harmful in 
tissues with a retained growth capacity. 
These mechanisms might also include proliferative senescence, as the senescent 
cells lose their ability to undergo apoptosis and produce some signals that stimulate 
epithelial cells with oncogenic mutations30. 
A third strategy for primary cancer prevention, which basically combines the two 
mentioned above, proposes that the cancer-prone phenotype of older animals, 
including humans, might reflect the combined effects of cumulative mutational load, 
enhanced epigenetic gene silencing, telomere dysfunction, and altered stromal 
milieu166.  
2.4 Regenerative medicine: the liver as a model. 
The idea that isolated cells can be introduced into the body and directed to repair 
irreversible damage in solid organs is gaining increasing attention167. 
The liver has been among the first targets for strategies based on transplantation of 
isolated cells. Over the past 15 years, significant progress in this field has been 
made by development of several experimental models for extensive liver 
repopulation via transplantation of isolated hepatocytes168-170. The urokinase-
plasminogen-activator (u-Pa) transgenic mouse model was the first to demonstrate 
the biological possibility of massive replacement of a disease liver via exogenously 
provided normal cells171-174. In this system, endogenous hepatocytes expressing the 
targeted u-PA transgene are selectively deleted and replaced by normal cells. 
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Based on this finding, hepatocytes isolated from a congenic donor where then 
transplanted into the u-PA mouse and tested for their ability to selectively proliferate 
in the host liver. Four to five weeks later, up to 80% of hepatocytes in the recipient 
liver were found to be of donor origin171, thereby confirming that the constitutive 
expression of the uPA transgene in resident hepatocytes generates a selective 
environment which favors the growth of cells with a normal phenotype. A similar 
principle of selective survival advantage seems to form the basis for the massive 
proliferation of transplanted cells in the liver of the fumaryl-acetoacetate-
hydroxylase- (Fah)-null mouse, a model for human hereditary tyrosinemia type I172. 
In both human and mice, the lack of Fah enzyme, involved in the tyrosine catabolic 
pathway, leads to accumulation of its substrate, fumaryl-acetoacetate (FAA) and its 
precursor maleyl-acetoacetate (MAA). Both FAA and MAA cause liver toxicity, 
which is found in tyrosinemia type I patients and includes progressive liver failure 
and development of hepatocellular carcinoma. 
In both cases, the essential feature of the model resides in the inherent genetic 
defect of resident cells which causes toxicity and leads to their selective death and 
replacement by wild type cells. 
An alternative means to create a differential in growth and/or survival capacity 
between the resident and the transplanted cell population is by targeting the latter, 
such that it acquires specific phenotypic properties which can be selected for in a 
normal background environment. In this case, the end result will be an organ 
repopulated with a genetically altered cell population. Based on this approach, 
hepatocytes over-expressing the human Bcl-2 transgene were introduced into 
normal recipient mice. Transplanted cells were then selected by differential killing of 
normal endogenous hepatocytes, via repeated systemic injections of a Fas/CD95 
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ligand, which caused single cell death in resident hepatocytes expressing only 
normal levels of the Bcl 2 protein 175. 
In our laboratory, we have used an alternative approach to develop a more general 
strategy for effective liver repopulation via isolated cell transplantation. In this 
system, donor hepatocytes are transplanted into a normal host liver in which  the 
endogenous growth capacity has been hampered by a preconditioning 
treatment173,176. 
However, in this case no “genetic” differential is present between the two cell types, 
i.e. both donor-derived cells and the recipient animal have a normal genetic 
background. The differential is imposed via external treatment of the host prior to 
cell transplantation. 
This transplantation model is based on exposure of the recipient animal to retrorsine 
(RS), a naturally occurring pyrrolizidine alkaloid (PA), that is able to impose a 
persistent block on the endogenous hepatocyte cell cycle177. PAs were originally 
studied because of their toxicity in animals, particularly sheep and cattle, where they 
cause both acute and chronic liver injury178. These agents are natural plant 
substances that are selectively taken up and metabolized by the liver to bioactive 
compounds that bind to DNA179. They produce a block in the hepatocyte cell cycle 
with accumulation of cells in late S and/or G2 phase
180-181. Although pyrrolizidine 
alkaloids are metabolized rapidly, their effect on hepatocyte proliferation lasts for 
weeks to months182.  
However, the mechanism by which mature hepatocytes are blocked in their 
proliferative response after treatment with RS has yet to be clarified and is still the 
subject of debate. There are data suggesting that the mitotic process itself is 
impaired, hence that the block is located very late in the mitotic cycle, i.e. in late S 
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or early G2 phase. This is supported by the observation of the induction of 
megalocytosis, which is thought to be a consequence of normal DNA, RNA and 
protein synthesis in the absence of cell division183.  
Under these conditions, normal hepatocytes, transplanted after the alkaloid has 
been metabolized, can selectively respond to growth stimuli and gradually 
repopulate the entire liver (>90% after 2 to 8 months post Tx, depending on the 
intensity of the growth stimulus applied)184-185. 
It was observed that normal hepatocytes undergo clonal proliferation when injected 
into the liver of RS-treated hosts. They integrate in the host liver and gradually 
repopulate the entire organ with a seemingly normal histology186. However, virtually 
no growth of transplanted hepatocytes occurs in the liver of syngeneic untreated 
recipients. 
 
2.4.1 Association between Liver Repopulation and Carcinogenesis. 
Interestingly, it was found that the original observations obtained using normal 
hepatocyte transplantation could be reproduced with hepatocytes isolated from 
preneoplastic liver nodules as the donor cell187. 
In a series of experiments, it was demonstrated that the growth-constrained 
microenvironment imposed by RS on endogenous hepatocytes could also sustain 
the selective expansion of transplanted nodular cells, resulting in the emergence of 
liver nodules and subsequent progression to hepatocellular carcinoma. 
Thus, the experimental findings obtained with this model provide compelling 
evidence that the same liver microenvironment that is permissive for the selective 
growth of normal transplanted hepatocytes also has the capacity to stimulate the 
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clonal expansion of altered/nodular hepatocytes and set the stage for their 
progression toward neoplasia. 
This association is intriguing and leads one to consider that these two processes 
may share common basic biological mechanisms; ie, the clonal growth of normal 
and altered/preneoplastic hepatocytes appears to be sustained by similar driving 
forces188. 
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3 Aim 
 
To explore possible biological and molecular mechanisms sustaining the growth of 
transplanted cells in a physiologically aged microenvironment and following a 
preconditioning treatment for massive liver repopulation. 
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4 Materials and Methods 
 
4.1 Animals and treatments 
A colony of DPPIV- Fischer 344 rats has been established in our laboratory. Donor 
DPPIV- F344 rats were purchased from Charles River (Milan, Italy). 
Animals were maintained on an alternating 12hr light/dark cycle with food (Purina 
Rodent Chow diet ) and water available ad libitum. All experiments were approved 
by the University of Cagliari Ethical Committee for Animal Experimentation; all 
animals received humane care in accordance with NIH Guidelines for the care and 
use of animals. Animals were killed by  exsanguination from the abdominal aorta 
while under light ether anesthesia. Livers were excised and samples from each lobe 
were snap frozen (for cryostat sections, protein and gene expression analysis) or 
fixed in 10% buffered formalin and embedded in paraffin (for histology).  
4.2 Retrorsine 
Pyrrolizidine alkaloids are naturally occurring genotoxic chemicals produced by a 
large number of plants from Symphytum and 
Senecio species. Retrorsine is one of the 
main alkaloids present in the Senecio 
species (figure 4). This plant is poisonous 
and has been found to contain  pyrrolizidine 
alkaloids which produce hepatic necrosis. 
 Fig.4 Senecio vulgaris 
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In animals, the major metabolic routes of pyrrolizidine  alkaloids are:  
 (a) hydrolysis of the ester groups; 
 (b) N- oxidation;  
(c) dehydrogenation of the pyrrolizidine  nucleus to pyrrolic derivates.  
 Routes (a) and (b) are believed to be detoxification mechanisms. Route (c) leads to 
toxic metabolites. Route (a) occurs in liver and blood; routes (b) and (c) are brought  
about in the liver by the microsomal mixed function oxidase  system189. 
Retrorsine is a 12-membered macrocyclic diester pyrrolizidine alkaloid with an α, β-
unsaturated double bond linked to the ester group at C-7 position of the retronecine 
base. The toxicity of retrorsine is due to the metabolic formation of the reactive 
pyrrolic metabolite; however, the mechanism of retrorsine-induced tumorigenicity is 
not clear. 
6 weeks DPPIV- old rats (with body mass 70-90g) were treated with 2 injections of 
retrorsine (RS, Sigma Chemical Co.), 30 mg/kg each, i.p., two weeks apart, or 
saline. RS was dissolved in diluted HCl (pH 2.5) followed by neutralization with 0.1N 
NaOH. 
 
Fig.5 RS structure 
Formula: C18H25NO6   
Molecular weight: 351.4 
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4.3 Generation of hepatic nodules 
Hepatocyte nodules were induced according to a well characterized experimental 
model in the rat190. Two-month-old male Fischer 344 rats (Charles River Breeding 
Laboratories) were injected with a single initiating dose of  diethylnitrosamine (200 
mg/kg body weight i.p.; Sigma), followed, 2 weeks later, by administration of 3 
consecutive daily doses of 2-acetyl-amino-fluorene (20 mg/kg) and coupled, on the 
4th day, by a single treatment with CCl4.   
 
4.4 The dipeptidyl-peptidase type IV-deficient rat model 
for hepatocyte transplantation 
Normal Fischer (F344) rats express a specific exopeptidase, dipeptidyl peptidase IV 
(DPPIV), in a characteristic pattern in the liver, restricted to the apical domain of the 
plasma membrane191. To follow the fate of donor hepatocytes into the recipient liver, 
the dipeptidyl peptidase type IV-deficient (DPPIV-) rat model can be used. In this 
system, cells isolated from a Fischer 344 rat expressing the enzyme DPPIV 
(DPPIV+) are transplanted into a syngeneic DPPIV deficient (DPPIV-) host, such that 
donor-derived cells can be detected in the recipient liver through simple 
histochemical and/or immunohistochemical techniques.  
Histochemical determination of DPPIV enzyme activity was performed as 
described176: 5-μM thick cryostat sections from frozen tissue were cut. Fixation was 
for 5 min in 95% ethanol/5% glacial acetic acid (99:1 vol/vol) at 0°C to −10°C, 
followed by a 5-min wash in 95% ethanol at 4°C. Air-dried slides were incubated for 
10–20 min at  RT in the substrate reagent: 2.5 mg Gly-Pro-4-methoxy-β-
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naphthylamide (Sigma) dissolved in 150 ml of dimethylformamide and mixed with a 
5 ml solution of Fast blue BB salt (Sigma) in PBS.  
 
4.5 Staining for senescence associated β-galactosidase 
activity 
Staining for SA-β-gal was performed according to published procedures107. 
Immediately before staining, X-Gal stock solution was prepared by dissolving 
20mg/ml X-Gal (Invitrogen, Carlsbed, CA) in dimetylformamide. SA-β-Gal staining 
solution was prepared as follows: 1 mg/ml of X-Gal stock solution were dissolved in 
40 mM citric acid in sodium phosphate, pH 6.0/5 mM potassium ferrocyanide/5 mM 
potassium ferricyanide/150 mM NaCl/2 mM MgCl2. Frozen sections of 10-µm 
thickness were fixed for 5’ in 4% formaldehyde/0.5% glutaraldehyde at 4°C, washed 
in PBS and incubated in fresh SA-β-Gal staining solution for 16h at 37°C. Sections 
were counterstained with Hematoxylin. 
 
4.6 Histology, Immunohistochemistry and 
Immunoflorescence 
Formalin-fixed, paraffin-embedded sections were stained with hematoxylin and 
eosin (H&E) according to standard procedures. Immunohistochemical staining for 
p21, p27 and mTOR was performed on paraffin embedded sections, following de-
wax and antigen retrieval with sodium citrate buffer (pH 6, 0.01M). Slides were 
blocked for 30’, incubated with primary antibodies (diluted in PBS) overnight at 4°C, 
and then incubated with AP-conjugated secondary antibodies. Detection of specific 
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signal was accomplished using the avidin/biotin alkaline phosphatase system 
(Vectastain ABC kit; Vector Lab, Burlingame, CA). Immunohistochemical staining 
for GSTP-P was performed on frozen sections fixed in acetic alcohol/ethylic alcohol, 
washed in PBS and blocked, incubated and detected with the same protocol for 
paraffin sections. Immunoflorescent staining for H2AX, 53BP1, ATM, Cyclin D1, 
KI67 and CD26 was performed on frozen sections, following fixation in cold acetone 
or methanol. Slides were blocked for 20’with goat or donkey serum, incubated with 
primary antibodies for 1 h at RT, followed by incubation (45’) with fluorescent-
conjugated secondary antibodies. Slides were counterstained with DAPI and 
images were acquired with an IX71 fluorescence microscope with CCD camera 
(Olympus, Tokyo, Japan). In table 1 the complete list of primary and secondary 
antibodies is reported. 
 
4.7 Western Blot 
Liver tissue samples were homogenized in RIPA lysis buffer containing protease 
Inhibitors and centrifuged at 12000 rpm for 30’ at 4°C. Protein concentration in 
supernatants was measured using the BCA method192. Samples (20µg protein) 
were prepared in Laemmli buffer, boiled at 95°C for 5’ then loaded into SDS-PAGE 
precast gels (Biorad, Hercules, CA) and run under denaturing conditions. Proteins 
were transferred onto nitrocellulose membranes (Amersham, UK), blocked with 5% 
non-fat milk for 1 h, followed by incubation with primary antibodies overnight at 4°C.  
Antibodies are listed in Table 1. Membranes were washed and incubated for 2 h 
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with the appropriate secondary antibody conjugated with HRP. Protein bands were 
detected using a chemoluminescent substrate (Biorad) and imaged onto Kodak film.  
 
4.8 RNA Isolation, RT-PCR and Real-Time qPCR 
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA) according 
to the manufacturer’s protocol. RNA integrity and purity were confirmed by 1% 
agarose gel electrophoresis and OD260/OD280 nm absorption ratio >1.8. Two 
grams of DNase-I treated RNA of each sample were reverse-transcribed by PCR 
using Promega reagents. The resulting cDNA was analysed by quantitative real-
time PCR using specific TaqMan assays and TaqMan Gene Expression Master Mix 
on an StepOne System (all from Applied Biosystems, Carlbad, CA). The rat specific 
assays were: IL-6 (Rn01410330_m1); β2-microglobulin (Rn00560865_m1); IL-8 
(Rn00578225_m1). For both assays the thermal profile was as follows: 50˚C for 2 
minutes, 95˚C for 10 minutes, 45 cycles at 95˚C for 15 seconds and 60˚C for 1 
minute. Fold change was calculated by the 2-ΔΔCT method193. 
Statistical analysis of results was performed with Student "t" test. 
 
4.9 DNA liver content 
The Diphenylamine (DPA) method is used for the determination of DNA content in 
tissue samples. This method is based on the colorimetric measurement of products 
formed from the reaction of o-hydroxylevulinylaldehyde (from the deoxyribose 
released after depurination of DNA) with diphenylamine in 1 N perchloric acid. 
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Sample preparation: 500 mg of liver per sample were homogenized in 1N perchloric 
acid (PCA) and centrifuged at 12.000 rpm for 15’ at 4°C. The pellet was then 
resuspended in 0.5N PCA and incubated at 70°C for 1.3 h while stirring.  
After incubation, samples were centrifuged at 12000 rpm for 15’ at 4°C and the 
supernatant was transferred into a new tube and kept on ice. Sample were diluted 
in 1:10 in 1ml of 0.5N PCA and then added with 2ml of DPA. The samples were 
incubated in the dark for 16-18 hours at room temperature, and absorbance values 
at 600nm were read at the spectrophotometer. A standard curve with Calf Thymus 
DNA was used as a reference. 
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TABLE 1 
  
Primary Antibody Brand Cat. No. 
p21 (M-19) Santa Cruz sc-471 
p27 (C-19) Santa Cruz sc-528 
ATM [2C1(1A1)] Abcam ab78 
H2AX (phosphor S139) Abcam ab2893 
53BP1 Abcam ab87097 
mTOR Abcam ab2732 
Cyclin D1 (DCS-6) Sigma C7464 
IL-6 Abcam ab6672 
TNF-α Abcam ab66579 
KI-67 (SP6) Abcam ab16667 
CDK4 (C22) Santa Cruz sc-260 
β-Actin Abcam ab8227 
GSTP1-1 CalBiochem 354212 
CD26 BD Pharm   559639 
Secondary Antibody Brand Cat. No. 
Anti-Rabbit IgG HRP-conj. Abcam ab16284 
Anti-Mouse IgG HRP-conj. Abcam ab6808 
Anti-Rabbit IgG Atto 550-conj. Sigma 43328 
Anti-Mouse IgG Atto 550-conj. Sigma 43394 
Anti-Rabbit IgG Dylight 488 conj. Abcam ab96899 
Anti-Mouse IgG Dylight 488 conj. Abcam ab96879 
 48   
 
 
 
 
 
 
 
 
 
 
5 RESULTS 
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5.1 The microenvironment of the aged rat liver supports 
the growth of transplanted hepatocytes isolated from 
hepatic nodules. 
Previous investigations conducted by our research group had revealed that isolated 
normal hepatocytes form larger clones of daughter cells when transplanted into the 
liver of old animals as compared to those formed in young recipients194. 
We then utilized a similar approach to verify whether the growth of transplanted pre-
neoplastic cells isolated from hepatic nodules was also dependent on the age of the 
recipient animal. 
Young (3-5 months old) or aged (18-20 months old) Fisher 344, DPPIV- rats were 
injected with 5x105 cells freshly isolated from DPPIV+ hepatocyte nodules. 
 
Experimental strategy         
                      
Hepatocyte nodules were induced according to a well-characterized experimental 
model in the rat. Two-month-old male Fischer 344 rats were injected with a single 
initiating dose of diethylnitrosamine (200 mg/kg body weight i.p.; Sigma) followed, 3 
weeks later, by exposure to a modified version of the Solt and Farber protocol to 
stimulate the growth of hepatocyte foci and nodules. Such a protocol consisted of 
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three consecutive daily doses of 2-acetylaminofluorene (20 mg/kg body weight, 
given by gavage tube; Sigma) followed, on the fourth day, by administration of CCl4, 
as described in Materials and Methods. Six months after the initial treatment, livers 
were perfused according to a standard two-step collagenase perfusion technique195. 
Large (>5 mm in diameter) nodules were physically separated from surrounding 
tissue and cells isolated from nodular tissue were suspended in Williams E culture 
medium (Sigma, cat No. W-4125) and prepared for transplantation experiments. 
Cell viability, determined by trypan blue dye exclusion, was 80-85%. Cells were 
delivered via portal vein infusion, suspended in 0.3 ml of Williams E medium. 
Animals were killed 8months after the transplant. 
Results are presented in Figures 6 and 7 and Tables 2 and 3. 
On macroscopic examination, no visible lesion were seen in any of the recipient 
animals transplanted at young age (figure 6, panel A); by contrast, almost all 
animals transplanted at 18-20 months of age and killed up to 8 month later, 
developed visible hepatic nodules, ranging from 1 to 8 mm in size, including five 
large tumours measuring up 3 cm of diameter (figure 6, panel B).  
 
Fig.6: Macroscopic appearance of the liver 8 months after transplantation of nodular cells. (A) No     
macroscopic nodules are visible in the liver of animals transplanted at 3 month of age. (B) Large 
nodular lesions are evident in the liver of animals transplanted at 18 months of age (arrows). 
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These findings were then confirmed and extended through histological and 
histochemical analysis (figure 7 and tables 2 and 3). Only rare, very small clusters 
of transplanted nodular hepatocytes were discerned in the liver of animals 
transplanted at 3-5 months of age and killed as late as 8 months post-injection 
(Figure 7, panel A). However, the same cell preparations were able to form hepatic 
nodules when transplanted in the liver of aged rats; these nodules had similar 
histological appearance to those isolated at the primary site (figure 7, panel C and 
D). 
          
Fig 7 nodular hepatocytes followed by  DPPIV staining: young rat (A ), old animal (B ) and old 
animals with HCC (C). Morphological analysis with  H&E  (D). 
 
 
Tables 2 and 3 report a summary of the distribution of nodular lesions in animals 
transplanted at different ages, and the average number of cells in DPPIV-positive 
hepatocyte clusters. 
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Table 2 
 
 
 
Table 3 
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5.1.1 Beta-galactosidase 
Senescence-associated β-galactosidase (SA-β-gal) is a marker enzyme described 
by Dimri et al.105, whose activity can be detected at pH 6 only in senescent cells. 
Although it does not appear to play any specific role in the induction of the 
senescent phenotype, it is still considered a useful marker of cell senescence, 
possibly reflecting the expansion of the lysosomal compartment in senescent 
cells107. 
The figure shows the increase of SA-β-gal activity in the animals killed at 26 months 
of age (transplanted at 18 months) compared with animals of 11 months 
(transplanted at 3 months). As expected, enzyme activity was virtually absent in the 
liver of young rats, while it was very prominent in older animals, indicating the 
progressive accumulation of senescent cells in the liver with age.  
                        
Figure 8: SA-β-gal staining in 2 animals transplanted at 3 months (A and B) and in 2 animals 
transplanted at 18 months (C and D) killed 8 months after. 
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5.1.2 Expression of IL-6 in animals of different age 
IL-6 is one of the main signaling pathways modulating the complex relationship 
between aging and chronic morbidity. There is evidence that free radical damage 
may be responsible for changes in the genetic control of IL-6 regulation, which, in 
turn, causes elevated levels of IL-6 in the elderly and in diseased patients196. 
Western Blot analysis and real time PCR show an increase of IL-6 levels in old 
animals compared with young rats. Especially in  the animals 26 months aged we 
can see the augmentation of IL-6 (figure 9). 
Another component of SASP, IL-8 is analyzed  by real time PCR but the IL-8 m-
RNA didn’t change  in the 3 classes of samples like IL-6. 
 
Fig.9 :Western Blot  analysis on IL-6  in young animals of 3 months (ctrl) ,11 months and 26 months 
after transplant of nodular hepatocytes. 
 
 
Fig.10: Gene expression  for  IL-6 (A) and IL-8 (B) 
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5.1.3 Inhibitors of cell cycle regulation 
Since cell senescence is often associated with altered regulation of CDK-Is, such as 
p21 and p27, the levels of expression of these proteins were analysed in rats of 
different age. As indicated in figure 11 and 12, both IHC and Western Blot showed 
no significant changes in the levels of these proteins. 
                         
Fig.11 Immunohistochemical  analysis of p21: A liver of animal transplanted at 3 months. B 
old liver transplanted at 18 months both killed 8 months after. 
 
 
 
                                                                  Fig. 12 Western Blot analysis of p27 
 
 
 
 
 56   
 
5.2 Cell senescence in liver repopulation 
The next series of experiments was aimed at probing into the hypothesis that cell 
senescence might be involved in the preconditioning effect for liver repopulation 
exerted by retrorsine197. After 1 week of acclimatization, rats were divided into two 
groups, of 12 animals each, and given either 2 injections of retrorsine 30 mg/kg 
each, i.p., two weeks apart, or saline. Four weeks after the last injection 6 control 
(untreated) and 6 RS-treated rats were killed, while the remaining 6 animals in each 
group underwent 2/3 partial hepatectomy (PH) and were killed 4 weeks after 
surgery. 
 
5.2.1 RS-exposed hepatocytes express senescence-associated β-
galactosidase. 
Exposure to RS caused a prominent increase of SA-β-gal expression in 
hepatocytes, observed as late as 4 weeks after treatment. The enzyme activity was 
detected throughout the liver parenchyma, although hepatocytes in zone 3 of the 
liver acinus were relatively spared (figure 13).  
Given our previous observations that PH is able to accelerate the kinetics of liver 
repopulation in this model, we analysed the expression of SA-β-gal in animals 
receiving RS followed by PH, according to the original protocol for hepatocyte 
transplantation173. Animals were killed 4 weeks after surgery. Results indicated that 
SA-β-gal was diffusely expressed in hepatocytes exposed to RS and PH, with no 
apparent zonal distribution, while very limited enzyme activity was detected in 
control animals receiving PH (panels c and d). 
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.                                                                                
 
 
Fig. 13 RS-exposed hepatocytes express senescence-associate β-Galactosidase. Histochemical 
staining for SA-β-gal in representative samples for: (A) control group; (B) RS-treated group; (C) 
Control+PH group; (D) RS + PH treated group. 
 
 
5.2.2 Hepatocyte megalocytosis induced by RS. 
Cellular enlargement (hypertrophy) is considered as one of the hallmarks of 
senescent cells, being the result of cell growth stimulation under conditions of 
replicative arrest. The presence of enlarged hepatocytes in rat liver exposed to PAs, 
including RS, has long been reported in the literature as one of the typical effects of 
these naturally occurring compounds109. We’ve measured the size of hepatocytes in 
rat liver exposed to RS under conditions that are conducive to liver repopulation, 
both in the absence and in presence of the proliferative stimulus of PH.  
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Fig. 14. RS treatment induces megalocytosis in hepatocytes. (A-D) Hematoxylin & Eosin staining in 
representative samples for: (A) control group; (B) RS-treated group; (C) Control+PH group; (D) RS + 
PH treated group. (E) To measure cell size, 10 high power fields/animal were counted in each group. 
*Significantly different from controls, p < 0.001; #Significantly different from RS only, p < 0.001; 
 
In figure 14, the histological appearance of the liver is reported. Enlarged 
hepatocytes are readily evident in panel b (RS-treated) compared to panel a 
(untreated control). It is noteworthy that exposure to RS alone did not cause other 
prominent alterations in liver histology, e.g. proliferation of bile ductular cells, 
chronic inflammation or fibrosis. 
In rats receiving RS+PH and killed 4 weeks after surgery hepatocyte megalocytosis 
was greatly enhanced  (panel d),  while no detectable change was seen in control 
animals after PH ( panels a and c). To measure cell size, images from H&E-stained 
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tissue sections were uploaded into a computer and cell boundaries were outlined in 
10 high power fields per animal. Computation was performed using Image Pro Plus 
program (Media Cybernetics, Inc. MD, USA). As shown in panel e of figure 14, 
highly significant differences were recorded between RS-treated and control groups, 
both prior to and post-PH, as well as between RS and RS+PH groups.  
 
5.2.3 DNA damage foci in RS-treated rat liver. 
One of the triggers of cell senescence is DNA damage. More specifically is a 
frequent association with the senescence phenotype198. Cells that senesce with 
persistent DDR signalling harbour typical nuclear foci, which have been referred to 
as DNA segments with chromatin alterations reinforcing senescence (DNA-
SCARS)15. These persistent foci contain proteins involved in chronic DDR, such as 
the ataxia telangiectasia-mutated (ATM) gene product. However, they are 
distinguishable from transient DDR complexes based on the presence of specific 
markers, including the H2AX and the p53 binding protein1 (53BP1).                  
Based on the well- established genotoxic potential of RS, we tested whether its 
induced hepatocyte senescence was associated with signs of persistent DDR in rat 
liver in vivo.  
 
Fig.15: DNA damage foci in RS-treated rat liver. Immunofluorescence staining for ATM expression in 
control animals and RS-treated animals, prior to- or after PH. 
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As presented in figure 15, 30-40% of hepatocytes from rats exposed to RS and 
killed 4 weeks later expressed ATM-positive nuclear foci, and this finding was even 
more frequent (60-65%) in hepatocytes from animals treated with RS+PH and killed 
4 weeks after surgery; by contrast, virtually no ATM-positive nuclear foci were found 
in control rats, either with no treatment or following PH . 
It was also investigated if RS-treated hepatocytes  express  H2AX and 53BP1, 
which are considered as indicative markers of persistent DDR. Both proteins were 
detected in hepatocyte nuclei of rats treated either with RS alone or with RS+PH.  
 
 
 
 
 
Fig. 16. DNA damage foci in RS-treated rat liver. Immunofluorescence staining for γ-H2AX  
expression in control animals and RS-treated animals, prior to- or after PH. 
 
 
Fig.17:DNA damage foci in RS-treated rat liver. Immunofluorescence staining for p53BP1                                                  
expression in control animals and RS-treated animals, prior to- or after PH. 
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More specifically, H2AX-positive hepatocytes were about 10% in both RS and 
RS+PH groups (figure 16), while 53BP1-expressing nuclear foci were present in 40-
45% of hepatocytes in rats given RS and increased to 65-70% in animals treated 
with RS+PH (figure 17). Both H2AX and 53BP1 were undetected (H2AX) or rarely 
detected (53BP1) in hepatocytes from control rat liver. These data are summarized 
in table 4. 
 
 
 Table 4: % DNA damage foci 
 
 
 
5.2.4 Up-regulation of cell cycle inhibitory proteins in RS-treated  rat 
liver. 
Progression of hepatocytes through the cell cycle is controlled by the activity of 
cyclin dependent kinases (CDKs), regulated by cyclins and by other proteins 
including CDK-inhibitors (CDK-Is)199. In order to investigate the molecular bases of 
the RS-induced, persistent replicative block, we analysed the expression two CDK-
Is of the Cip/Kip family, p21 and p27, which are known to interact with complexes of 
cyclins D and E and their CDKs targets. Western blot analysis of total liver proteins 
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revealed over-expression of p21Cip1 in animals exposed to RS compared to controls, 
and a further increase in p21 protein was seen in the group receiving RS+PH. 
 
 
Fig 18. Cell cycle inhibitory proteins are up-regulated in RS-treated rat liver. Expression of p21  
protein was measured in control animals and RS-treated animals, prior to or after PH. 
 
 
This pattern of results was consistent with data obtained through immuno-
histochemical staining of liver sections with an antibody specific to p21; the protein 
was found to be highly expressed in nuclei of RS-induced megalocytes, both in the 
absence of PH and, more so, in animals killed 4 weeks after PH, while it was rarely 
detected in control groups, either untreated or following PH (figure 19) 
 
Fig.19: Immunohistochemical staining for p21 
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Results were similar when the expression of p27Kip1 was analysed. Both western 
blotting and immunohistochemical staining revealed a prominent increase of p27 
levels in the liver of rats exposed to RS, and the effect was further amplified 
following PH (figure 20 and 21). Interestingly, increased expression of p27 was also 
observed in control rats as late as 4 weeks after PH. 
 
 
 
Fig.20: Western Blot analysis of p27 expression 
 
 
 
Fig.21: Immunohistochemical staining for p27 
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5.2.5 The increased expression of positive regulators of cell growth and 
cell-cycle progression in RS-exposed liver.  
Stimulation of cell growth and cell cycle progression is considered as the other side 
of the coin, opposite to cell cycle arrest, sustaining the emergence of a senescence 
phenotype200. In an earlier report, we described the over-expression cell cycle 
related gene products, including cyclin D1, CDK4 and PCNA, in rat liver exposed to 
RS201. In the present study, we extended the analysis to the mammalian target of 
rapamycin (mTOR), which plays a pivotal role at the crossroads of cell metabolism, 
integrating energy balance and cell growth signals202. There is in fact evidence to 
indicate that activation of mTOR under conditions of cells cycle arrest leads to cell 
senescence198. Results are presented in figure 22: increased levels of mTOR 
protein were detected in the liver of rats exposed to RS compared to untreated 
controls (figure 22); such a difference was even more prominent in groups receiving 
PH and killed 4 weeks later, despite the fact that PH caused a decrease in mTOR 
levels in both RS and control groups. We also confirmed the accumulation of cyclin 
D1 in rat liver treated with RS, as already reported199; moreover, a further increase 
in this protein was seen in the group receiving RS+PH and killed 4 weeks later 
(figure 22). 
 
 
 
Fig.22. Increased expression of positive cell-cycle regulators in RS-treated liver. Western Blot 
analysis of mTOR and Cyclin D1 expression in control animals and RS treated animals, prior to- or 
post-PH 
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5.2.6 IL-6 is over-expressed in rat liver exposed to RS. 
A most intriguing feature of cell senescence is the associated secretory phenotype 
(SASP)22. This pattern of gene expression includes a series of cytokines, growth 
factors and other products that are secreted by senescent cells and can exert a 
plethora of biological effects, mostly limited to the local tissue microenvironment122. 
The specific composition of SASP is likely to vary depending on cell and tissue type. 
However, a consistent finding is the presence of the inflammatory cytokine 
interleukin 6 (IL-6), which has also been implicated in reinforcing the senescence 
phenotype through autocrine and/or paracrine mechanism86. 
 Based on this evidence, it appeared reasonable to explore the possibility that 
alterations in IL-6 expression might also be present along in association with other 
markers of cell senescence in rat liver exposed to RS. As documented in figure 23 
and 24,  both IL-6 mRNA and protein levels were found to be increased in animals 
treated with RS according to the protocol for liver repopulation; a further increase in 
both parameters was seen in RS+PH group, and this was particularly prominent for 
IL-6 mRNA.  
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 Fig.23 Quantitative mRNA expression of IL-6 in all four experimental groups. *Significantly different 
from control, p < 0.001 
 
 
 
 
Fig.24: western blot protein analysis of IL-6 in all four experimental groups. 
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5.2.7  Regulation of IL-8 following exposure to RS  
Rat cytokine-induced neutrophil chemoattractant 1 (CINC-1) belongs to the CXC 
chemochine family and is a counterpart a human growth-related oncogene (GRO) in 
the Interleuchin-8 (IL-8) family. In rats, CINC-1 plays a key  role in neutrophil-
mediated inflammatory disease by attracting neutrophils to the site of inflammation. 
Since IL-8 has also been reported to be a component of SASP in some cell 
systems, we investigated its expression profile during hepatocyte senescence 
induced by RS.  
 
                                           Fig.25: m-RNA analysis of IL-8 
 
5.2.8 Up regulation of TNF-α 
The pro-inflammatory cytokine TNF-α is an important mediator of the inflammatory 
responses with multiple biologic activities. It has been implicated in the 
pathogenesis of cancer, mainly in the context of chronic inflammation, because it 
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triggers DNA damage, angiogenesis, invasion and metastasis203.                   
Western Blot analysis revealed an increase of this cytokine in livers treated with RS. 
 
 
 
                                
Fig.26: Western blot analysis on TNF-α 
 
5.2.9 Regenerative nodules do not express markers of cell senescence. 
Remarkably, no signs of phenotypic senescence were seen in regenerative nodules 
developing in rats given RS and PH. These nodules have long been described in 
the literature204 and are composed of small hepatocytes which are able to withstand 
the cell cycle block imposed by RS on surrounding parenchymal cells. They slowly 
expand and replace the entire liver, in a process unfolding over several months that 
we have referred to as endogenous liver repopulation205. The cell of origin of small 
hepatocytes is still a matter of debate206-207. 
 
Fig.27: H&E of regenerative nodule (see arrows) in RS-treated liver. 
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When regenerative nodules were probed for the presence of markers of cell 
senescence, they were found to express a phenotype that was in sharp contrast to 
that of surrounding megalocytes. In fact, small hepatocytes composing regenerative 
nodule showed no significant SA-β-gal activity; in addition, mTOR expression was 
low in these nodule compared to surrounding liver (figure 28). 
  
 
Fig 28 Histological analysis of liver tissue samples from animals treated with RS + PH and killed 4 
weeks after surgery. Regenerative nodules are indicated by arrowheads. SA-β-gal histochemical 
staining (right); mTOR immunohistochemical staining (left). 
 
 
 
Only rare nuclear staining for p21 or p27 CDK-Is (figure 29).         
 
Fig.29 Immunohistochemical staining for p21 (right) and p27 (left) in regenerative nodule and                            
surrounding liver 
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Furthermore, cyclin D1-positive nuclei were common in RS-exposed megalocytes, 
while they were rare in regenerative nodules; conversely, numerous Ki67-
expressing hepatocytes were found inside regenerative nodules while they were 
rarely seen in the megalocytic surrounding liver (figure 30).  
 
Fig.30 immunofluorescence staining for Cyclin D1 (green) and KI67 (red). Regenerative nodules are 
indicated by a dashed line. 
 
Similarly, we found that CDK4 protein, which associates with cyclin D1, was 
frequently detected in the nuclei of enlarged hepatocytes, while it was virtually 
absent in small hepatocytes of regenerative nodules (figure 31). 
 
 
Fig.31 immunofluorescence staining for CDK4 (red). 
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5.3 Normal hepatocyte transplantation delays the 
emergence of chemically-induced pre-neoplastic 
nodules in rat liver 
 
The intriguing analogies existing between liver repopulation and carcinogenesis, 
suggest that these two processes may share common pathogenetic mechanisms188.  
Within this conceptual framework, normal cells could possibly be used to 
competitively counteract the selective growth of altered cells during early stages of 
carcinogenesis. Thus, it was investigated whether strategies aimed at normalizing 
the microenvironment of a chronically and/or irreversibly injured liver tissue prone to 
cancer, may help reduce the risk of neoplastic disease208. 
In this experiment, we aim to investigate whether transplantation of normal cells in 
the context of an injured, neoplastic-prone microenvironment might impact on the 
evolution of carcinogenic process. 
A rat model of chemically-induced hepatocarcinogenesis was used. Animals were 
given a single dose of diethylnitrosamine (DENA), followed by two injections of 
retrorsine (RS), a pyrrolizidine alkaloid that imposes a persistent block on 
hepatocyte cell cycle. At the end of this protocol, rats were either given no further 
treatment or injected, via the portal circulation, with 4 million normal hepatocytes 
isolated from a syngeneic donor. A second group of animals was similarly exposed 
to DENA+RS protocol followed by transplantation of normal hepatocytes. 
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5.3.1 The induction of hepatic nodules by sequential exposure to 
DENA+RS. 
 
Experimental strategy 
 
 
 
As predicted, sequential exposure to DENA and RS resulted in the occurrence of 
numerous hepatocyte nodules, both on the liver surface (up to 30/liver, mean 18±5, 
and on sectioning.  
 
 
 
Fig.32 Liver samples of rats exposed to DENA+RS (panels A and C) or DENA+RS+Tx (panels B 
and D and E) and killed 4 months later. Panel A (DENA+RS) shows numerous white-greyish nodules 
present on liver surface, while no such lesions are present in liver lobes of panel B (DENA+RS+Tx). 
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Nodular lesions were whitish-grey in colour and resembled those induced by other 
classical protocols of chemical hepatocarcinogenesis in the rat, both on 
macroscopic appearance and upon histological analysis (figure 32). 
They also expressed the GST 7-7 marker enzyme, further supporting their putative 
preneoplastic nature (figure 33).  
 
 
Fig.33 Whole cryostat sections of the same livers processed for immunohistochemical detection 
of GST 7-7.  A: note the presence of several GST 7-7-positive lesions (dark blue) in the liver 
(DENA+RS), while few such lesions are present in panel B  (DENA+RS+Tx).  
 
 
 
The histology of transplanted and repopulated livers was also remarkably different 
compared to non-transplanted group (figure 34). Only residual cords of megalocytes 
were seen in between clusters of donor-derived cells in transplanted rats. The latter 
displayed normal size, normal histology and were perfectly integrated into the host 
liver, with no evident demarcation from resident hepatocytes. Proliferation of oval 
cells was also greatly reduced in livers receiving hepatocyte transplantation. 
Surrounding liver was mainly occupied by enlarged (megalocytic) hepatocytes, with 
rare clusters of very small hepatocytes that have been referred to as regenerative 
nodules177; mild to intense proliferation of oval cells was also observed . 
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Fig.34 Liver samples of rats exposed to diethylnitrosamine + retrorsine ((DENA+RS) and killed 4 
months later (see text for details). Panel A shows at least 3 white-greyish nodules (arrows) in the 
caudate lobe .B-E histological appearance of H&E stained liver sections is shown; panels A and B 
show a liver nodule (thick arrows), sharply demarcated from surrounding enlarged hepatocytes 
(megalocytes, thin arrow in panel C). In panels and  D the typical alterations induced by RS on rat 
liver can be observed, with extensive megalocytosis and moderate to intense proliferation of ductular 
epithelial cells (panel E, thin arrows).  
 
 
 
5.3.2  Liver size and hepatocyte proliferation. 
 
Parameters related to liver size and liver DNA content in both transplanted and non-
transplanted groups were also measured. No significant differences were seen in 
final body weight and liver weight. Interestingly, a slight increase in liver DNA 
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content was observed in the group receiving transplantation (6.42±0.12 vs. 
5.64±0.34 mg DNA/liver/per 100g b.w., p<0.05). 
 
 
 
Fig.35 Slight increases in relative liver weight and liver DNA content were observed in the 
group receiving transplantation, although only the latter reached a level of statistical 
significance (panels C and D) 
 
 
 
 
5.3.3 Liver repopulation by transplanted cells in DENA+RS-treated liver. 
 
We have repeatedly shown that pre-exposure to RS sets the stage for extensive 
repopulation of the host liver by transplanted normal hepatocytes207. However, no 
 76   
 
studies had been published so far on the effect of a combined treatment with DENA 
and RS on liver repopulation.  
Percent of host liver replacement by donor-derived cells was therefore evaluated in 
these experiments using a computer assisted image analyzer. High levels of 
repopulation were observed in all transplanted animals, with an average of 53±7% 
of total liver replacement by DPP-IV-expressing hepatocytes (figure 36). The 
distribution of transplanted cells clusters was generally homogeneous throughout 
the recipient lobes, although some areas displayed lower levels of repopulation.  
 
 
Fig.36 Panel A:whole cryostat section of a liver samples processed for dual histochemical-
immunohistochemical detection of DPP-IV activity (orange-rust) and GST 7-7 expression; note the 
extensive repopulation of the host liver by DPP-IV positive, donor-derived hepatocytes. In panel B a 
photomicrograph of a transplanted liver is shown: only residual endogenous megalocytes were 
present (thin arrow) 
 
 
5.3.4 The effect of hepatocyte transplantation on the incidence of nodules 
in the liver of DENA+RS-treated rats. 
Another aim was to determinate  whether transplantation of normal hepatocytes and 
the associated extensive liver repopulation had any influence on the growth of 
nodules induced by sequential exposure to DENA and RS. The number of GST 7-7-
positive focal lesions was greatly reduced in rats receiving DENA+RS and 
transplantation as compared to the control group given DENA+RS only (3±2 vs. 
19±8 lesions per cm2). This was also reflected in the relative area occupied by 
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nodular lesions, below 2% in the group receiving DENA+RS and transplanted cells 
(1.8±0.3%), down from a control value of 8.5±2.8%; this represents a net decrease 
of almost 80% between group 1 and group 2. Furthermore, the mean size of the 3 
largest GST 7-7 positive nodules found in each animal of the two groups was 
reduced by a factor of about 5 in transplanted vs. non-transplanted rats.  
 
 
Fig. 37 number and size distribution of GST 7-7 expressing lesions is compared, while panel B 
shows the percent area occupied by nodular lesions in each group.  
 
  
 
 
 
 
Fig. 38 In panel C, the 3 largest GST 7-7-positive nodules from each animal were considered, and 
their mean size was compared in the two groups. Finally, panel D reports the extent of liver 
repopulation by transplanted cells in rats exposed to DENA+RS+Tx. Data are mean±SE. 
Significantly different from control, *p<0.05; #p<0.001 (two-tailed t-test) 
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5.3.5 SA-β-GAL decrease in transplanted animals 
 
The activity of SA-β GAL  in the transplanted animals is reduced compared with the 
animals that received only DENA and RS. Two serial sections of animals 
transplanted after 2 months show that the liver is repopulated by normal 
hepatocytes and only in the area not repopulated is there some β-gal activity. 
(figure 39 panel A and B). DENA-RS exposed hepatocytes express senescence-
associate β-Galactosidase in all the surrounding liver (panel C) but not inside the 
nodules (panel D). 
 
 
 
 
Fig.39 A: DPPIV activity in the repopulated liver. B-D SA-β-gal activity detected in an animal 
transplanted with normal hepatocytes (B) and in a disease liver treated with DENA+RS (C and D).  
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5.3.6 DNA damage foci 
As reported in the preceding chapter, exposure to RS results in the appearance of 
persistent DNA damage foci, containing proteins involved in the chronic DDR. It 
became therefore important to ascertain whether transplantation of normal 
hepatocytes and the associated liver repopulation would alter the distribution of 
such foci in DENA+RS-exposed rat liver. 
As reported in figures 40 and 41, the number of nuclei expressing γ-H2AX is higher 
in livers treated with DENA+RS without transplant compared to animals receiving 
DENA+RS followed by hepatocyte transplantation. Similar findings were seen for 
the expression of 53BP1-positive nuclear foci. 
 
 
 
Fig.40. Immunofluorescence staining for H2AX and 53BP1 expression in DENA- RS-treated 
animals, with or without transplant. Nuclei are stained with DAPI. 
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The double staining in immunofluorescence shows that the transplanted normal 
hepatocytes (CD26 positive) were negative for the presence of γ-H2AX, while rare 
surrounding residual megalocytes expressed the senescence marker. 
 
 
 
 
 
Fig.41 Immunofluorescence staining for H2AX( green), CD26(red) and merge in liver treated with 
DENA-RS and transplanted with normal cells. Nuclei are stained with DAPI. 
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6 Discussion 
 
The first relevant observation presented in this thesis relates to the complex 
relationship between aging and cancer. As already mentioned in the Introduction,  
the basic observation that increasing age is the strongest risk factor for the 
neoplastic disease, has no satisfactory explanation as yet. This observations would 
concern both human and other animal species. We provide evidence to suggest 
that an altered tissue landscape induced by the aging process can foster the growth 
of altered cells, setting the stage for neoplastic progression and the emergence of 
overt cancer.  
When altered hepatocytes isolated from chemically-induced rat liver nodules were 
orthotopically transplanted into either young (3- to 5-mos old) or aged (18- to 20-
mos old) recipients, two important findings were observed: 
 Firstly, very limited expansion of transplanted nodular hepatocytes was seen 
in the liver of young animals, indicating that pre-neoplastic cell populations 
isolated from hepatic nodules are not endowed with any measurable degree 
of growth autonomy, in that they were unable to form nodules when 
transferred in the orthotopic environment of a young host. This in turn 
indicates that their focal growth at the primary site is also likely to depend on 
stimuli originating from the local microenvironment, as opposed to intrinsic 
alterations in the cell cycle control. In this respect, they do in fact behave like 
normal hepatocytes174. 
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 Secondly, the same preparations of isolated nodular cells grew significantly 
upon injection into aged host liver, generating large cell clusters, expanding 
to form new hepatic nodules and progressing, in a few cases, to HCC. These 
results clearly indicate that the microenvironment of the aged liver is able to 
provide critical component(s) to sustain the selective growth of transplanted 
nodular hepatocytes, implying a possible a mechanistic explanation for the 
link between aging and cancer.   
Grisham and co-workers were among the first to suggest a direct role for the local 
tissue microenvironment to explain the association between cancer and aging208. 
These authors reported that tumorigenic liver epithelial cells injected directly into the 
hepatic parenchyma of young and old rats could grow and form tumors only in the 
latter group, while the liver of young recipients was able to suppress the neoplastic 
phenotype of the injected cells209-210. 
Recent work by DeGregori et al.211 has extended a similar concept to the 
hematopoietic system. Following a series of elegant studies, they have proposed 
the hypothesis that the aged microenvironment of the bone marrow selects for the 
emergence of leukemogenic cell clones, thereby contributing to the increase in 
leukaemia in older age. The results presented in this dissertation are in line with the 
above propositions, providing further insights into the complex relationship between 
aging and cancer. In our studies, hepatocytes isolated from well characterized 
primary liver nodules were used and no in vitro passage was involved in the 
transplantation experiments; thus, the continuity of the carcinogenic process was 
essentially maintained, adding to the relevance of the results to the in vivo situation. 
Furthermore, nodular hepatocytes that were used in our studies are not fully 
neoplastic and they cannot be propagated in vitro under standard conditions, 
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behaving in this regard like the normal cell counterparts. In this respect, this is the 
first report showing that the aged liver microenvironment supports the selective 
growth of a pre-neoplastic cell population, extending the impact of the aging 
process to an early phase of the carcinogenic process. On the other hand, our 
findings also bear mechanistic implications towards explaining the link between 
aging and cancer. One of the factors that have been invoked to account for the 
increased frequency of cancer in the elderly is a decline in the immune-surveillance, 
such that altered cells on the pathway to cancer are no longer detected and deleted 
as age progresses210-212. While such proposition does fall within the broader realm 
of microenvironment-orientated hypotheses, our present results are not consistent 
with a major involvement of the immune system in this phenomenon, for at least two 
reasons. 
 Firstly, small clusters of transplanted hepatocytes were found in the liver of 
young recipients as late as 8 months post-transplantation, indicating that they 
were not deleted by the immune system.  
 Secondly, similar results were observed when normal hepatocytes were 
transplanted into the liver of young animals, indicating that the lack of growth 
of transplanted hepatocytes in liver microenvironment of the younger host is 
not unique to nodular/altered cells.      
      Taken together, such findings do not support the contention that a failing 
immune system can explain the increased growth of transplanted cells (including 
normal hepatocytes!) in the aged host liver. As expected, the liver of aged animals 
expressed increased levels of SA-β-gal, which is still considered as a reliable 
marker of cell senescence. Cell senescence has been initially interpreted as a fail-
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safe mechanism to avoid the risk of neoplastic transformation in cells harbouring 
damaged DNA197. However, its biological significance has been reconsidered to 
incorporate the overwhelming evidence that senescent cells can in fact foster the 
growth of premalignant and malignant cells. These effects are at least partly 
mediated by a specific secretory pattern, referred to as SASP213-214, which includes 
a growing list of factors secreted by senescent cells, comprising cytokines, growth 
factors and proteases. A major component of SASP is the inflammatory cytokine IL-
6, which is also able to reinforce the senescence phenotype through an autocrine 
loop mechanism122. Interestingly, liver tissue from older animals expressed higher 
levels of IL-6 compared to younger controls, consistent with the activation of a 
SASP response in the aging liver. While being expressed by senescent cells, IL-6 is 
also a cytokine with an established role in liver regeneration and repair215-216, thus 
making it a likely candidate contributing to the growth of transplanted nodular 
hepatocytes in the aged liver. 
The above results obtained during transplantation studies in the aged liver are 
similar, in principle, to those observed using the RS-based model for liver 
repopulation, although the magnitude of the phenomenon is far greater in the latter 
case. However, it was still more surprising to find that the analogies between age-
induced and RS-induced alterations in the liver microenvironment extend beyond 
the effect on hepatocyte transplantation. As reported in this thesis, exposure to RS 
was associated with widespread, persistent changes in resident hepatocytes that 
were consistent with the induction of a senescence phenotype. Such changes 
include diffuse expression of SA-β-gal, induction of markers associated with cell 
cycle arrest, such as p21 and p27; signs of persistent activation of a DDR with the 
presence of DNA-SCARS, as evidenced by ATM-, 53BP1- and γ-H2AX-positive 
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nuclear foci; over-expression of positive regulators of cell growth and cell cycle 
progression, such as mTOR, cyclin D1, CDK4 and PCNA. In addition, RS-exposed 
liver expressed high levels of IL-6, the pro-inflammatory cytokine that is also a major 
component of the SASP, as mentioned above. It is noteworthy that all alterations 
induced by RS were long lasting, in that they were detected as late as 6 weeks after 
exposure to the alkaloid, implying the seemingly irreversible nature of these 
changes. Thus, it is apparent that the microenvironments of the aged and RS-
exposed livers share both the ability to stimulate the growth of transplanted 
hepatocytes and a fundamental attribute of the aging process, i.e. the emergence of 
senescent cells; in both cases, the effect of RS is of far greater magnitude. 
According to a most comprehensive model proposed in the literature, the 
senescence phenotype emerges when a cell integrates two types of signals: one 
that reads for growth and one that imposes a block in the replicative cycle199,217.              
If these two signals persist for a sufficient length of time, one of the possible 
outcomes is cell senescence. For example, DNA damaging agents do not induce 
senescence in quiescent cells; however, they do so if the presence of persistent 
DNA damage and cell cycle arrest is coupled with growth promoting stimuli. Under 
these conditions, the cells express markers related to cell cycle block, such as p53, 
p16, p21 or p27, as well as markers associated with growth stimulation, including 
cell hypertrophy and up-regulation of cell cycle related cyclins. While this model is 
largely built on data derived from in vitro studies, our present results suggest that a 
similar scenario occurs in rat hepatocytes exposed to RS in vivo, according to a 
treatment protocol that is conducive to massive liver repopulation by transplanted 
hepatocytes174,177. RS and other related pyrrolizidine alkaloids have long been 
known for their ability to cause a persistent cell cycle block on hepatocytes178, 
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possibly via induction of DNA damage15. Enlarged, hypertrophic hepatocyes 
(megalocytes) emerging in RS-treated rats were unable to complete DNA synthesis 
or undergo mitotic division218. Our present studies suggest that this is possibly 
mediated via induction of CDK-inhibitors p21 and p27.  
Considering the other side of the coin, i.e. the growth stimulatory signals, RS-
treated hepatocytes also express high levels of positive regulators of the cell cycle, 
including, cyclin D1, CDK4 and PCNA200, suggestive of a state of hyper-stimulation 
imposed on a background of replicative arrest.  In addition, a relevant finding of the 
present studies is that exposure to RS is also associated with a long lasting 
increase in the levels of mTOR protein, which plays a central role in the integration 
of cell growth signals200,206. There is evidence to indicate that mTOR pathway is 
critically involved in determining two possible cell fates, quiescence or senescence, 
depending on the conditions associated with the cell cycle block: inhibition of mTOR 
leads to cellular quiescence, while activated mTOR drives the cell to 
senescence199,201. 
It was interesting to find that regenerative nodules emerging in rat livers exposed to 
RS+PH did not express markers related to cell senescence; in fact, their phenotype 
was in sharp contrast to that observed in surrounding tissue (figure 28-29). The cell 
of origin of these nodules is still controversial204-205; however, it is well established 
that they slowly expand and eventually repopulate almost entirely the surrounding 
liver183, replacing megalocytic hepatocytes in a process that can be likened to 
endogenous repopulation219. Such sequence of events indicates that small 
hepatocytes in regenerative nodules have a competitive growth advantage 
compared to surrounding senescent hepatocytes, possibly driven, at least in part, 
by IL-6220, secreted by the same surrounding megalocytes. However, it is important 
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to point out that, when isolated normal hepatocytes are transplanted into the liver of 
RS-treated animals, they are able to overrun the emergence of endogenous 
regenerative nodules, leading to massive repopulation by donor-derived cells174,177. 
As already mentioned, the senescence phenotype has historically been interpreted 
as a means to oppose or minimize the possibility for the emergence of neoplastic 
cells in tissues experiencing widespread damage, including DNA damage. While 
this view is still largely entertained, it is now complemented, and often obscured, by 
a more recent propositions which regards the accumulation of senescent cells as a 
powerful driving force for neoplastic disease in several tissues. This  hypothesis 
was first formulated by Judith Campisi over a decade ago221 and has since been 
receiving increasing support222. Thus, while the essence of cell senescence 
continues to be interpreted as barrier against the risk of cancer223, it is now well 
established that senescent cells can fuel the neoplastic process by altering the 
tissuemicroenvironment70.  
This effect is exerted, at least in part, via expression of a peculiar phenotype which 
is referred to as SASP, as described in the Introduction. A main component of 
SASP are cytokines, including pro-inflammatory cytokines such as IL-6. It is 
therefore noteworthy that both aging and exposure to RS were associated with 
increased IL-6 expression in the liver tissue. 
However, it is easily predictable that the significance of cell senescence is still to be 
fully elucidated. Far from being a mere passive state of cells at the end of their 
replicative lifespan, the senescent phenotype is already emerging as a new state of 
differentiation which can exert far reaching effects on tissue function, cell turnover 
and repair224. The results presented in this thesis are in line with the widely held 
view that cell senescence can contribute to the emergence of neoplastic disease, by 
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stimulating the growth of transplanted altered/nodular hepatocytes; this effect was 
observed both in aged animals and in animals exposed to RS. However, it was also 
observed that the same liver microenvironment was also able to support the 
expansion of transplanted normal hepatocytes, suggesting that cell senescence and 
the associated SASP can indeed sustain normal tissue regeneration and repair, 
under appropriate conditions. This implies that factors secreted by senescent cells 
are not specific for altered cells on the pathway to cancer, but they can also be 
exploited by normal cells expressing specific receptors for those factors. In this 
scenario, a cell competition strategy is possibly enforced, whereby the prevailing 
cell type will be the one that is better equipped to integrate the stimuli generated by 
the surrounding microenvironment, including, as a relevant component,             
senescent cells and their SASP. 
The last section of this thesis represents an initial attempt to test the hypothesis 
outlined above. It describes studies aimed at reversing the RS-induced alterations 
in the liver microenvironment and, in doing so, at verifying whether this would 
modulate the growth of preneoplastic lesions promoted by RS. Animals given the 
genotoxic agent diethylnitrosamine (DENA), followed by RS, developed large 
hepatocyte nodules within a few months. Transplantation of normal hepatocytes in 
the context of a neoplastic-prone liver microenvironment is able to exert a significant 
impact on the development of nodular pre-neoplastic lesions. Injection of 4x106 
hepatocytes, isolated from a normal syngeneic donor, into the liver of a recipient 
animal pre-exposed to a carcinogenic protocol, resulted in a sharp delay and/or 
reduction in the incidence of hepatocyte nodules. This effect was accompanied by 
an extensive repopulation of the host liver by transplanted cells, resulting in a 
profound modification of the neoplastic-prone tissue landscape.    
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These results represent a proof of principle that an altered microenvironment is 
indeed a powerful driving force in neoplastic progression; most importantly, they 
clearly indicate that strategies aimed at “normalizing” such an altered 
microenvironment might impact on the rate of progression of neoplastic process. 
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